SCODiA Report by MLBI Lab

Single-Cell Transcriptomic and Genomic Landscape of Human Colorectal Cancer Reveals Key Therapeutic Opportunities

This report details the single-cell transcriptomic and genomic profiling of human colon tissue, revealing profound alterations in colorectal cancer (CRC). We observed a clear segregation of normal and tumor cells, with malignant Intestinal Epithelial cells demonstrating widespread aneuploidy. The tumor microenvironment is significantly remodelled, characterized by an immunosuppressive shift in T cell and macrophage populations, alongside the activation of cancer-associated fibroblasts. Critical cell-cell interaction networks are dysregulated, pointing to novel mechanisms of immune evasion and tumor support, while intracellular pathways related to cell cycle progression and metabolism are profoundly activated in tumor cells.

Contents

0. Dataset overview
1. UMAP Visualization of Colon scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy
2. Major Cell Type Score and Ploidy Distribution on UMAP
3. Marker Gene Expression Validation Across Colon Cell Subsets
4. Copy Number Variation Analysis in Intestinal Epithelial Cells
5. UMAP Visualization of CNV Patterns by Cell Type, Ploidy, Condition, and Sample
6. Minor Cell Type Population Analysis in Colorectal Tissue
7. T Cell Subsets Population Analysis in Colorectal Cancer
8. Differential T Cell Subset Proportions in Colorectal Cancer
9. Macrophage Subset Population Analysis in Colorectal Cancer
10. Macrophage Subset Population Shifts in Colorectal Cancer
11. Ploidy Status of Intestinal Epithelial Cells in Normal and Tumor Conditions
12. Remodeling of Cell-Cell Interaction Landscape in Colorectal Cancer: Normal vs. Tumor Microenvironment
13. Condition-Specific Cell-Cell Interaction Patterns in Colorectal Cancer
14. Condition-Specific Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Colorectal Cancer
15. Surfaceome Marker Expression in Intestinal Epithelial Cells of Colorectal Cancer
16. Fibroblast Condition-Specific Surfaceome Markers in Colorectal Cancer
17. Condition-Specific Surfaceome Markers in Colorectal Cancer CD4+ T Cells
18. Dysregulation of Cell Cycle Pathway Genes in Intestinal Epithelial Cells of Colorectal Cancer
19. Gene Ontology (GSA) Analysis of Intestinal Epithelial Cells in Colorectal Cancer
20. Gene Set Enrichment Analysis (GSEA) of Cell Types in Colorectal Cancer
21. Discussion
22. Query List

0. Dataset overview

Dataset Summary

• AnnData Dimensions: This dataset contains 48,033 cells and 20,683 genes.
• Observed Metadata: Key observational columns include samples, Condition, Location, MSI_Status, celltype_major, celltype_minor, celltype_subset, ploidy_dec, cluster, and various CNV-related metrics.
• Gene Metadata: Variable columns store variable_genes, chr, spot_no, and cytogenetic_band.
• Origin: The data is from human tissue, specifically Colon.
• Conditions: Data is segmented into 'normal' and 'tumor' conditions.
• Cell Type Hierarchy:
• Major: T cell, B cell, Intestinal Epithelial cell, unassigned, Stromal cell, Endothelial cell, Myeloid cell, Mast cell.
• Minor: T cell CD4+, B cell, Intestinal Epithelial cell, Plasma cell, ILC, T cell CD8+, unassigned, Fibroblast, Endothelial cell, Macrophage, Mast cell, Dendritic cell, NK cell, Smooth muscle cell.
• Subset: A more granular list including T cell (Naive), B cell (Follicular), Goblet cell, Enterocyte, and many others.
• Tumor Context: Tumor identification was requested during processing. The resolved tumor-origin cell type is 'Intestinal Epithelial cell'. Ploidy analysis shows 93.7% Diploid, 6.1% Aneuploid, and 0.1% Unclear cells.
• CNV Data: Copy Number Variation (CNV) estimates are available.
• Reference Condition: 'normal' is used as the reference for differential analyses (DEG_vs_ref, GSEA_vs_ref, GSA_vs_ref_up).

Precomputed Results

• uns['CCI'] and uns['CCI_sample']: Cell-cell interaction results (CellPhoneDB) available per condition and per sample.
• uns['DEG']: Differential Expression Gene (DEG) results for each celltype_minor comparing one condition against the rest.
• uns['GSEA']: Gene Set Enrichment Analysis (GSEA) results for each celltype_minor comparing one condition against the rest.
• uns['GSA_up']: Gene Ontology (GSA) results for each celltype_minor comparing one condition against the rest.

Inferred Biological Context

• The dataset likely pertains to Colorectal cancer, based on the 'Colon' tissue, 'tumor' condition, identification of 'Intestinal Epithelial cell' as the tumor-origin cell type, and the presence of aneuploid cells. The specific stage or subtype of cancer is not explicitly detailed.

1. UMAP Visualization of Colon scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP (Uniform Manifold Approximation and Projection) plots generated from single-cell RNA sequencing data of human Colon tissue. These visualizations are designed to provide an overview of the dataset's structure, highlighting the distribution of cells based on different annotations: condition (normal vs. tumor), sample, major, minor, and subset celltype classifications, and ploidy_dec (diploid, aneuploid, unclear). The primary goal is to assess the overall cellular heterogeneity, the impact of tumor transformation on cell populations, and the quality of cellular annotations.

Visual Summary

Condition

The UMAP colored by condition reveals a clear separation between normal (maroon) and tumor (dark purple) cells in several regions of the embedding. A large, densely populated cluster on the left side of the UMAP contains a significant proportion of normal cells but also a substantial presence of tumor cells. Conversely, a distinct, more compact cluster on the bottom-right is almost exclusively composed of tumor cells. Other smaller clusters show varying degrees of mixing or segregation. This indicates profound transcriptional differences between normal and tumor cells, but also shared populations or states.

Sample

The sample UMAP displays a diverse array of colors, each representing a unique sample. Critically, cells from different samples generally appear well-interspersed within the major clusters. This suggests that the biological variability between cell types and conditions dominates the UMAP structure, with minimal evidence of strong sample-specific batch effects that would cause cells from individual samples to cluster independently.

Celltype_major

The celltype_major UMAP shows well-defined and largely distinct clusters corresponding to broad cell types. T cell (cyan) forms the largest cluster on the left, consistent with its mixed normal/tumor presence observed in the condition plot. Intestinal Epithelial cell (Ent.Epi, orange) forms a prominent, distinct cluster, particularly the one on the bottom-right that largely overlaps with the tumor condition. B cell (maroon), Stromal cell (teal), and Myeloid cell (light green) also form identifiable clusters, with Endothelial cell (Endo, red) and Mast cell (yellow) forming smaller, more scattered groups. unassigned cells (dark purple) are sparsely distributed, indicating that most cells are successfully categorized at this level.

Celltype_minor

The celltype_minor UMAP provides a more refined view of cell populations. Within the large T cell cluster, T cell CD4+ (cyan) and T cell CD8+ (dark blue) are visibly distinguishable, reflecting expected T cell subtypes. The Intestinal Epithelial cell (Ent.Epi, orange) cluster remains robustly defined. Plasma cell (teal) cells emerge as a distinct population from B cell (maroon), and various Myeloid subsets like Macrophage (Mac, light green) and Dendritic cell (DC, red) are also evident. The separation of these finer cell types confirms the high resolution of the single-cell data and the annotation process.

Ploidy_dec

The ploidy_dec UMAP is particularly informative in the context of cancer. Diploid (yellow) cells are widely distributed across most of the UMAP landscape, as expected for normal somatic cells. In stark contrast, Aneuploid (maroon) cells are highly concentrated within specific regions, most notably the large cluster on the bottom-right. This Aneuploid cluster shows a strong spatial overlap with the Intestinal Epithelial cell cluster and the cells annotated as tumor. Unclear cells (dark purple) are very few and scattered.

Celltype_subset

The celltype_subset UMAP offers the highest granularity of cell type annotations. Within the previously identified Intestinal Epithelial cell cluster, numerous specialized subsets are visible, including Enterocyte, Goblet cell, Paneth cell, Crypt cell, Tuft cell, and Enterochromaffin cell, among others. Similarly, the T cell clusters further resolve into T cell (Naive), T cell (Treg), T cell (Th1), T cell (Cytotoxic), etc. This detailed resolution allows for an in-depth characterization of the cellular heterogeneity within both normal and diseased colon tissue.

Biological Interpretation

The integrated view of these UMAPs provides crucial biological insights into colorectal cancer.

1. Tumor-associated Cellular Remodeling: The condition UMAP clearly demonstrates that colorectal cancer induces significant shifts in the cellular landscape, with distinct cellular states or compositions emerging in the tumor microenvironment. The partial overlap of normal and tumor cells within the large T-cell cluster may suggest common immune cell types infiltrating both normal and tumor tissues, or a spectrum of activation states.
2. Malignant Cell Identification: The strong co-localization of Aneuploid cells (maroon in ploidy_dec) with the Intestinal Epithelial cell cluster (orange in celltype_major/minor) and the tumor condition (dark purple in condition) provides compelling evidence for Intestinal Epithelial cells as the tumor-originating cell type. Aneuploidy is a hallmark of cancer, and its specific enrichment within the tumor-associated epithelial population strongly supports their malignant transformation.
   • This finding aligns directly with the provided context that 'Intestinal Epithelial cell' is the 'Resolved tumor-origin cell type' and the presence of aneuploid cells in the dataset.
3. Heterogeneity of the Tumor Microenvironment: The detailed celltype_subset UMAP highlights the immense cellular diversity within the colon tissue, encompassing various immune cell subsets, stromal components, and specialized intestinal epithelial cells. The differential distribution of these subsets across normal and tumor regions implies a dynamic tumor microenvironment that orchestrates interactions between various cell types, which is critical for cancer progression and response to therapy.
4. Data Quality and Annotation Robustness: The consistent clustering of cells across different levels of cell type annotation (major, minor, subset) and the clear segregation based on biological states (condition, ploidy_dec) underscore the high quality of the single-cell data processing and cell type annotation. The effective mitigation of batch effects, as suggested by the sample UMAP, ensures that observed patterns are biologically meaningful rather than technical artifacts.

Annotation Notes

The provided UMAPs demonstrate a high quality of cell type annotation and embedding structure.

• Cell types are generally well-separated and align logically with hierarchical classification (major to subset).
• The ploidy_dec annotation strongly corroborates the condition and celltype assignments for identifying tumor cells, increasing confidence in the cancer cell population.
• The minimal presence of 'unassigned' cells across cell type plots indicates robust classification for the vast majority of cells.
• The visual absence of strong sample-specific clustering suggests effective data integration, allowing for reliable biological comparisons across different samples.

2. Major Cell Type Score and Ploidy Distribution on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP plots to visualize the distribution of major cell types and their corresponding scores, along with the ploidy status (diploid, aneuploid, unclear) across the single-cell RNA-seq dataset. The HiCAT_major_score plots demonstrate the confidence of cell type assignments by projecting aggregated marker gene expression onto the UMAP embedding. The ploidy_dec plot specifically highlights cells identified as aneuploid, which is critical in identifying tumor cells within the inferred colorectal cancer context. The celltype_major plot provides the overall cell type annotation for comparison.

Visual Summary

The UMAP embedding reveals distinct clusters of cells, indicating different cellular identities based on their transcriptional profiles.

• HiCAT_major_score Plots (T cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Enteric neuron, Intestinal Epithelial cell): Each plot displays the score for a specific major cell type, with higher scores (yellow/green) indicating stronger expression of characteristic marker genes for that cell type.
  • T cell scores are high in a large, distinct cluster on the left side of the UMAP, aligning well with the celltype_major plot's T cell cluster.
  • B cell scores are elevated in a cluster in the upper-right region, consistent with the B cell annotation.
  • Myeloid cell scores show high values in a cluster in the upper-middle region.
  • Mast cell scores are notably high in a small, localized cluster in the top-middle part of the UMAP.
  • Endothelial cell scores are prominent in a small, distinct cluster in the far upper-right.
  • Stromal cell scores are high in a cluster in the upper-middle, adjacent to Myeloid cells.
  • Intestinal Epithelial cell scores are distinctly high in a large cluster located in the lower-right quadrant of the UMAP. This cluster appears somewhat more diffuse compared to some immune cell clusters.
  • Enteric neuron scores are relatively low across most of the UMAP, with small pockets of slightly elevated scores. This suggests a minor population or less distinct marker expression compared to other major cell types.
• Ploidy_dec Plot: This plot shows the ploidy status for each cell.
  • A significant population of Aneuploid cells (colored maroon) is primarily concentrated within the large cluster in the lower-right quadrant of the UMAP.
  • The vast majority of cells are Diploid (light yellow), forming the bulk of most other clusters.
  • Unclear ploidy cells are very rare and scattered.
• celltype_major Plot: This serves as the reference for major cell type annotations.
  • It clearly delineates the different major cell type clusters across the UMAP, confirming the spatial segregation observed in the HiCAT_major_score plots.
  • The large cluster in the lower-right, dominated by aneuploid cells, is consistently annotated as "Ent.Epi" (Intestinal Epithelial cell).

Biological Interpretation

The UMAP visualization effectively separates cell populations based on their transcriptomic profiles, with each HiCAT_major_score plot validating the specific marker expression within its corresponding major cell type cluster. This indicates a robust and accurate cell type annotation for the dataset.

A key observation is the strong co-localization of high Intestinal Epithelial cell scores with the aneuploid cell population. The large cluster in the lower-right, identified as Intestinal Epithelial cells, shows a clear enrichment of aneuploid cells. This finding strongly supports the initial inference that Intestinal Epithelial cell is the Resolved tumor-origin cell type and that the dataset pertains to Colorectal cancer, where aneuploidy is a hallmark of malignancy in epithelial cells https://pubmed.ncbi.nlm.nih.gov/30743132/.

The presence of diverse immune cell populations (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Fibroblasts, Endothelial cells, Smooth muscle cells, inferred from "Stromal cell" and "Endothelial cell" major types, and specific minor/subset types in obs metadata) forming distinct clusters suggests a complex tumor microenvironment. T cells, in particular, form a large cluster, indicating a significant immune infiltrate. The spatial separation of these immune and stromal cell types from the core Intestinal Epithelial cell/tumor cluster is also evident. The HiCAT_major_score for each cell type generally matches the corresponding celltype_major cluster, reinforcing the quality of cell type annotation. For example, high T cell scores perfectly overlap with the T cell cluster, and similarly for B cells and Myeloid cells, suggesting confident assignments.

Clinical or Translational Implications

The robust identification of distinct cell populations and the clear association of aneuploidy with the Intestinal Epithelial cell cluster are crucial for understanding the cellular landscape of colorectal cancer. This validates the Intestinal Epithelial cell as the likely tumor component and confirms the presence of malignant cells.

The well-defined separation of immune and stromal compartments provides a foundation for further investigations into the tumor microenvironment (TME) in colorectal cancer. Characterizing these non-malignant cell types and their interactions with tumor cells can reveal mechanisms of immune evasion, angiogenesis, and metastasis, which are critical for developing targeted therapies and prognostic markers https://pubmed.ncbi.nlm.nih.gov/35921764/. The accurate cell type annotations, as validated by the HiCAT_major_score plots, ensure that subsequent analyses (e.g., differential gene expression, cell-cell interaction) are performed on correctly identified populations, enhancing the reliability of any translational insights.

3. Marker Gene Expression Validation Across Colon Cell Subsets

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot, visualizing the expression patterns of key genes across various celltype_subset categories identified in the single-cell RNA-seq dataset from Colon tissue. The primary goal is to assess the specificity and enrichment of these marker genes within their assigned cell subsets, thereby validating the cell type annotations. Each dot represents a gene-cell type pair, with its size indicating the fraction of cells within that group expressing the gene, and its color intensity reflecting the mean expression level. Genes are grouped by their primary cell type association, as indicated by the red boxes and corresponding labels.

Visual Summary

The dot plot effectively illustrates distinct expression profiles for various celltype_subset groups.

• Specificity and Enrichment: A prominent diagonal pattern of dark red, large dots is observed, indicating that specific sets of genes are highly expressed and widely detected within their corresponding celltype_subset groups. This suggests strong enrichment and specificity of the identified markers.
• Marker Gene Grouping: Genes are organized into distinct groups along the x-axis, with red bounding boxes highlighting clusters of markers predominantly expressed by particular cell types or closely related cell types. For instance, B cell subsets show expression of B cell-specific transcription factors, while various T cell subsets display characteristic immune cell markers.
• Expression Levels and Prevalence: The color intensity (mean expression) and dot size (fraction of expressing cells) consistently show that the selected markers are not only highly expressed but also present in a large proportion of cells within their designated subsets, further supporting their utility as robust markers.
• Cell Type Abundance: The bar plot on the right displays the total number of cells for each celltype_subset, revealing the relative abundance of different populations in the dataset. T cell (Naive), T cell (Cytotoxic), T cell (Tfh), and Plasma cells are among the most abundant populations, while Enterochromaffin cells, Endothelial tip cells, and NK cells are less numerous but still well-represented above the minimum threshold.

Biological Interpretation

The observed marker gene expression patterns strongly support the celltype_subset annotations within this colon single-cell dataset.

• B Cell Subsets: B cell (Breg), B cell (MZ), and B cell (Memory) subsets are clearly characterized by the expression of canonical B cell transcription factors like POU2F2 and POU2AF1 (OCT2 and OBF-1), confirming their identity as distinct B cell populations.
• Intestinal Epithelial Cells: The various intestinal epithelial cell subsets, including Crypt cells, Enterocytes, Enterochromaffin cells, Goblet cells, Microfold cells, and Paneth cells, exhibit expected lineage-specific markers. For example, KRT20 and CDH17 are broadly expressed across epithelial cells, MUC2 and TFF3 are specific to Goblet cells, LYZ is a classic Paneth cell marker, and TRPM5 identifies Tuft cells. Enterocytes show high expression of FABP1. Endothelial tip cells show expected markers like ANGPLT2, ESM1, ADM, and DLL4.
• Stromal Cells: Fibroblasts are well-identified by the high expression of collagen genes (COL1A1, COL1A2, COL3A1) and other stromal markers like LUM, DCN, and ACTA2 (indicative of myofibroblasts), consistent with their extracellular matrix production and structural roles.
• Myeloid Cells: Macrophage subsets (M1, M2A, M2B, M2C) show high expression of general macrophage markers such as CD68, and specific genes like STAT1, SOCS3, and PTGS2, which are often associated with inflammatory responses or polarization states. Mast cells are distinctly marked by TPSAB1, TPSB2, GATA2, KIT, and SRGN.
• Lymphoid Cells: Various T cell subsets, including T cell (Cytotoxic), T cell (Naive), T cell (Tfh), T cell (Th1), T cell (Th17), T cell (Th2), T cell (Th22), and T cell (Treg), are well-differentiated by their signature markers. For instance, CD8A/B and GZMB for cytotoxic T cells, FOXP3 and CTLA4 for Tregs, LEF1 for naive T cells, RORA for Th17 cells, and GATA3 for Th2 cells. NK cells are characterized by KLRD1, FCGR3A, and granzymes. Plasma cells exhibit robust expression of JCHAIN, MZB1, XBP1, PRDM1, TNFRSF17, and SDC1, confirming their antibody-producing identity.
• ILCs: ILC1 and LTI cells show expected lymphoid markers like CD69, CD44, CD7, and ITGA4.

Overall, the marker expression patterns align with established knowledge of cell type-specific gene expression, providing strong evidence for the accuracy and robustness of the celltype_subset annotations in this dataset.

Annotation Notes

The plot provides strong visual validation for the celltype_subset annotations. The identified marker genes show high specificity and enrichment within their respective cell populations, with minimal promiscuous expression across unrelated cell types. This indicates that the sub-clustering and annotation efforts for this single-cell dataset have been successful in distinguishing biologically meaningful cell populations based on their transcriptional signatures. The consistency between observed marker expression and known cell identities suggests a high quality of cell type classification at the celltype_subset level.

4. Copy Number Variation Analysis in Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a copy number variation (CNV) heatmap focusing on Intestinal Epithelial cells, grouped by individual samples. The heatmap displays the log2 ratio of copy number estimations (log2(CNR)) across the genome, indicating regions of amplification (red) and deletion (blue). Accompanying the heatmap is a summary of significantly amplified regions, providing mean log2(CNR) values for specific cytogenetic bands across samples and the frequency of these amplifications. This aims to identify recurrent genomic alterations within the presumed tumor cells (Intestinal Epithelial cells) in the context of Colorectal Cancer.

Visual Summary

CNV Heatmap for Intestinal Epithelial Cells

The main heatmap illustrates the genomic landscape of copy number alterations in various Intestinal Epithelial cell clusters (labeled T_cac1 through T_cac14, presumably representing tumor-derived Intestinal Epithelial cells from different samples or sub-clusters). Several common patterns emerge:

• Recurrent Amplifications: Notable regions of amplification (red) are observed across multiple T_cac groups. Key amplified regions highlighted are:
  • Chromosome 8 (8q22.1:8q24.3): A consistent amplification is visible across many T_cac samples.
  • Chromosome 12 (12q24.31:12q24.33, 12q24.33:12q34): This region also shows frequent amplification.
  • Chromosome 17 (17q12:17q21.31): A strong and widespread amplification is evident in this region.
  • Chromosome 20 (20p13:20q11.22): Several samples show amplification in this area.
• Recurrent Deletions: Fewer widespread deletions are apparent, but one notable region includes:
  • Chromosome 5 (5q31.1:5q31.2): This region shows deletion (blue) in several T_cac samples.
• Heterogeneity: While common patterns exist, there is also heterogeneity in CNV profiles across different T_cac groups, suggesting inter-sample variability or subclonal evolution within the tumor.

Summary of Significantly Amplified Copy Numbers

The accompanying summary plots provide a quantitative view of the observed amplifications:

• Mean Log2(CNR) Heatmap: This heatmap shows the mean log2(CNR) values for specific cytogenetic bands across selected T_cac samples. It corroborates the visual patterns from the larger heatmap, confirming higher mean copy numbers (darker blue, values > 0) in regions like 8q22.1:8q24.3, 12q24.31:12q24.33, 12q24.33:12q34, 17q12:17q21.31, and 20p13:20q11.22.
• Frequency of Amplification Bar Plot: This plot highlights the frequency with which specific cytogenetic bands are amplified across the analyzed T_cac samples. The most frequently amplified regions include:

17q12:17q21.31 (frequency 0.75)

8q22.1:8q24.3 (frequency 0.62)

12q24.31:12q24.33 (frequency 0.50)

20p13:20q11.22 (frequency 0.50)

These frequencies indicate that these amplifications are recurrent events in the Intestinal Epithelial cells, reinforcing their potential role in tumor biology.

Biological Interpretation

The observed recurrent copy number amplifications in the Intestinal Epithelial cell population, identified as the tumor-origin cell type, are highly relevant to colorectal cancer (CRC) pathology.

• ERBB2 Amplification (17q12:17q21.31): The amplification of the 17q12:17q21.31 region, which harbors the *ERBB2* gene (also known as *HER2*), is a significant finding. *ERBB2* is a well-established oncogene whose amplification and overexpression drive proliferation and survival in various cancers, including a subset of CRC PubMed Search: ERBB2 colorectal cancer. Its high frequency (0.75) suggests it's a common event in these tumor cells.
• 8q22.1:8q24.3 Amplification (EIF3E, INTS8): Amplification of 8q22.1:8q24.3, encompassing genes like *EIF3E* and *INTS8*, is also frequently observed. *EIF3E* (Eukaryotic Translation Initiation Factor 3 Subunit E) plays a role in protein synthesis and has been implicated in promoting cell proliferation and survival in various cancers UniProt: EIF3E. *INTS8* (Integrator Complex Subunit 8) is part of a complex involved in processing small nuclear RNAs, and its dysregulation could impact gene expression and cellular homeostasis, potentially contributing to oncogenesis.
• Other Amplifications (e.g., Chr 12, Chr 20): Recurrent amplifications on chromosomes 12 and 20 are also notable. These regions often contain genes involved in cell cycle regulation, signaling pathways, and cell growth that can contribute to tumorigenesis when amplified. For example, 20q amplification is frequently observed in CRC and often correlates with advanced disease.

The presence of these amplifications in Intestinal Epithelial cells strongly supports their cancerous nature and points towards specific genomic mechanisms driving tumor development or progression in the inferred colorectal cancer context. The recurrent nature across multiple samples further highlights their potential importance as driver events.

Clinical or Translational Implications

The identification of recurrent copy number amplifications in the tumor-origin Intestinal Epithelial cells has several potential clinical and translational implications for colorectal cancer:

• Biomarker Potential: The frequent amplification of *ERBB2* (HER2) suggests its potential as a prognostic and predictive biomarker in CRC. Patients with *HER2* amplified tumors may respond differently to certain therapies.
• Therapeutic Targets: *ERBB2* is a well-established therapeutic target in other cancers (e.g., breast, gastric cancer) with approved HER2-targeted therapies (e.g., trastuzumab, pertuzumab, lapatinib). The presence of *ERBB2* amplification in these CRC cells suggests that a subset of CRC patients might benefit from such targeted therapies, which is an active area of research and clinical trial investigation in CRC PubMed Search: HER2 targeted therapy colorectal cancer.
• Disease Subtyping: The specific pattern of CNVs could contribute to molecular subtyping of CRC, potentially guiding treatment strategies or identifying patients at higher risk of progression.
• Research Avenues: The identified amplifications, including those involving *EIF3E* and *INTS8*, could prompt further research into their precise functional roles in CRC and their potential as novel therapeutic targets or vulnerabilities.

This analysis provides valuable insights into the genomic landscape of tumor cells in colorectal cancer, highlighting specific alterations with known or potential relevance to disease progression and treatment.

5. UMAP Visualization of CNV Patterns by Cell Type, Ploidy, Condition, and Sample

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five UMAP plots generated using CNV (Copy Number Variation) patterns to visualize the single-cell RNA-seq data. The UMAPs are colored by key metadata annotations: celltype_major, celltype_minor, ploidy_dec (ploidy declaration), condition (normal vs. tumor), and sample. The primary goal is to assess cell type identities, ploidy states, and their distribution across conditions and samples based on their genomic integrity, particularly in the context of colorectal cancer.

Visual Summary

Cell Type and Ploidy Distribution

The UMAPs reveal a clear and structured separation of cell populations based on their CNV profiles.

• celltype_major and celltype_minor UMAPs: Distinct clusters corresponding to major and minor cell types are visible. A large, prominent cluster on the right side of the UMAP is predominantly composed of Intestinal Epithelial cell (Ent.Epi). Immune cells like T cell and B cell form separate, well-defined clusters, mainly on the left and upper-left regions. The finer celltype_minor resolution further differentiates immune cell subsets (e.g., T cell CD4+, T cell CD8+) while maintaining the overall structure.
• ploidy_dec UMAP: This plot strikingly highlights a distinct segregation of Aneuploid cells (dark red) into the prominent Intestinal Epithelial cell cluster previously identified. The vast majority of other cell types are declared Diploid (light yellow) and occupy the remaining, larger portion of the UMAP. A small number of Unclear cells (purple) are scattered. This strongly indicates that the Intestinal Epithelial cell population within this dataset is largely aneuploid.

Condition and Sample Distribution

• condition UMAP: This plot shows that the region enriched for Aneuploid Intestinal Epithelial cell is almost exclusively composed of cells from the tumor condition (purple). The normal condition (dark red) cells are primarily found in the Diploid regions, intermingled with tumor cells, reflecting the presence of normal cells within the tumor microenvironment.
• sample UMAP: Cells from different samples are generally well-mixed within their respective cell type and ploidy clusters, suggesting effective integration and that the UMAP structure is driven by biological differences rather than strong sample-specific technical variations. However, the Aneuploid Intestinal Epithelial cell cluster from tumor samples appears to be derived from a mix of various "T_cac" and "B_cac" samples, further supporting a tumor-specific population.

Biological Interpretation

The UMAP embeddings, derived from CNV information, provide strong evidence for genomic instability in a specific cell population.

1. Confirmation of Tumor-Origin Cell Type: The distinct cluster of aneuploid cells, aligning perfectly with Intestinal Epithelial cell types and originating from tumor samples, robustly confirms Intestinal Epithelial cell as the Resolved tumor-origin cell type. This is a foundational finding for understanding colorectal cancer in this dataset.
2. Genomic Instability in Tumor Cells: The clear separation of Aneuploid cells from Diploid cells, with aneuploidy predominantly found within the Intestinal Epithelial cell population in the tumor condition, directly demonstrates the genomic instability characteristic of cancer cells. This is a hallmark of tumor progression and malignancy.
3. Tumor Microenvironment Composition: The presence of Diploid cells from both normal and tumor conditions, intermingled outside the aneuploid cluster, indicates the diverse cellular composition of the tumor microenvironment. This includes various immune cells (T cells, B cells, Myeloid cells) and stromal cells that are not aneuploid, yet contribute to the tumor ecosystem.
4. Data Quality and Integration: The sample UMAP suggests good integration of data from different samples, as cells from distinct samples largely overlap within biological clusters rather than segregating by sample origin. This enhances confidence that observed patterns are biological signals rather than batch effects.

Annotation Notes

The UMAPs confirm the quality of the cell type annotations and the reliability of the ploidy and condition assignments within the single-cell dataset. The clear segregation of Aneuploid cells to Intestinal Epithelial cells from tumor samples provides robust validation for the inferred tumor-origin cell type. This visual inspection supports the biological relevance of the downstream analyses.

6. Minor Cell Type Population Analysis in Colorectal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot illustrating the relative proportions of different minor cell types across individual samples from both normal colon tissue and colorectal tumor tissue. Each bar represents 100% of the cells within a single sample, with color-coded segments indicating the percentage of each celltype_minor. This visualization helps to identify shifts in cellular composition associated with the disease state (tumor vs. normal) and to assess sample-to-sample heterogeneity.

Visual Summary

The plot is divided into two main panels: "normal" (left) and "tumor" (right), displaying the cell type composition for several samples under each condition.

• Normal Samples: These samples generally show a more diverse and relatively balanced cellular landscape. Key components include a substantial proportion of Intestinal Epithelial cells (light orange), along with various immune cells like T cell CD4+ (light green-blue), T cell CD8+ (darker green-blue), and B cells (dark red). Stromal cells such as Fibroblasts (orange) and Endothelial cells (red-orange) are present in smaller proportions.
• Tumor Samples: A striking feature in the tumor samples is the substantial increase in the proportion of Intestinal Epithelial cells in many (e.g., T_cac2, T_cac3, T_cac1, T_cac7, T_cac8), often dominating the cellular composition and exceeding 75% in some cases. Concurrently, other cell types, including various immune cells, appear relatively diminished in these epithelial-rich tumor samples. However, there is notable heterogeneity among tumor samples; some (e.g., T_cac10, T_cac12, T_cac11) show a lower proportion of Intestinal Epithelial cells and a relatively higher presence of immune cells (e.g., T cell CD4+, T cell CD8+, B cell, Plasma cell) and stromal cells (e.g., Fibroblast).

Specific Cell Type Trends

• Intestinal Epithelial cell: Generally expanded in tumor samples, consistent with its identification as the tumor-origin cell type.
• Fibroblast: Appears to be increased in some tumor samples (e.g., T_cac2, T_cac3) compared to normal tissue, suggesting stromal activation.
• Immune Cells (T cells, B cells, Macrophages): While their *relative* proportions may decrease in tumor samples heavily dominated by epithelial cells, their *absolute* numbers or infiltration patterns are highly variable across different tumor samples. Some tumor samples show substantial immune cell populations, potentially indicating an immune-infiltrated tumor microenvironment.
• "unassigned" cells: Represent a small, consistent fraction across most samples in both conditions, indicating a minor portion of cells not definitively classified at this minor cell type resolution.

Biological Interpretation

The observed shifts in cell type proportions between normal and tumor colon tissues provide significant insights into the biology of colorectal cancer.

1. Tumor Cell Expansion: The prominent increase in Intestinal Epithelial cells in many tumor samples strongly supports the identification of this cell type as the tumor-origin. This expansion reflects the uncontrolled proliferation of malignant epithelial cells, a hallmark of carcinoma. The variability in the proportion of these cells among tumor samples could indicate differences in tumor cellularity, presence of necrosis, or the extent of immune and stromal infiltration.
2. Tumor Microenvironment Remodeling:
   • Stromal Activation: The increased representation of Fibroblasts in certain tumor samples (e.g., T_cac2, T_cac3) points towards an active desmoplastic reaction, a common feature in colorectal cancer. Fibroblasts, particularly cancer-associated fibroblasts (CAFs), play crucial roles in tumor progression, metastasis, and immune evasion by secreting extracellular matrix components, growth factors, and cytokines PubMed Search: "cancer associated fibroblasts colorectal cancer".
   • Immune Landscape: The relative decrease of immune cells in epithelial-dominant tumor samples suggests immune cell exclusion or dilution by the expanding tumor mass. Conversely, tumor samples with higher proportions of immune cells (e.g., T_cac10, T_cac12, T_cac11) may represent immune-inflamed tumors, which can be associated with different clinical outcomes and responses to immunotherapy. The presence of various immune cell types (T cells, B cells, Macrophages, Plasma cells) highlights the complex interplay between the immune system and cancer in the tumor microenvironment PubMed Search: "tumor microenvironment colorectal cancer immunity".
3. Heterogeneity within Tumor Samples: The considerable variation in cell type composition among different tumor samples underscores the intra-tumor and inter-patient heterogeneity inherent in colorectal cancer. This heterogeneity can influence disease progression, treatment response, and prognosis.

Clinical or Translational Implications

The distinct cellular landscape observed in colorectal tumors compared to normal tissue has several clinical and translational implications:

1. Biomarker Identification: The altered proportions of specific cell types, such as the increase in Intestinal Epithelial cells and Fibroblasts, or shifts in immune cell infiltrates, could serve as potential diagnostic or prognostic biomarkers. For instance, the density and composition of immune cell infiltrates (e.g., CD8+ T cells) are known to correlate with patient survival in colorectal cancer GeneCards: CD8A.
2. Therapeutic Targets: Understanding the cellular composition of the tumor microenvironment can guide therapeutic strategies. For example:
   • High proportions of Intestinal Epithelial cells indicate a primary tumor likely responsive to therapies targeting epithelial cancer cells.
   • Increased Fibroblasts suggest a prominent stromal component that could be targeted to disrupt tumor support and enhance drug delivery.
   • The presence and specific types of immune cells can inform immunotherapy approaches. Tumors with robust T cell infiltration might be more responsive to checkpoint inhibitors, whereas "immune-desert" tumors might require strategies to overcome immune exclusion.
3. Patient Stratification: The observed inter-sample heterogeneity suggests that patients with colorectal cancer might be stratified into distinct subgroups based on their tumor microenvironment composition. This stratification could help in predicting treatment response and personalizing therapeutic interventions.
4. Monitoring Disease Progression: Changes in cell type populations could potentially be monitored during treatment to assess response or identify resistance mechanisms.

7. T Cell Subsets Population Analysis in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot illustrating the relative proportions of different T cell subsets, alongside some innate lymphoid cell (ILC) and NK cell populations, within individual samples from normal colon tissue and colorectal tumor tissue. The plot compares the immune cell composition at the 'celltype_subset' level, specifically focusing on populations identified under the broader 'T cell' major cell type, across varying conditions. This allows for a detailed examination of how the immune microenvironment, particularly T cell-mediated immunity, shifts between healthy and cancerous states.

Visual Summary

The stacked bar plot provides a clear visualization of the T cell and related innate lymphoid cell population distribution across individual samples, grouped by 'normal' and 'tumor' conditions.

• Dominant Populations in Normal Tissue: In normal colon samples, T cell populations are predominantly composed of T cell (Naive) and T cell (Cytotoxic) cells, which together constitute a large fraction of the observed cells.

Shifts in Tumor Microenvironment:

• Decreased Naive and Cytotoxic T cells: In tumor samples, there is a discernible reduction in the relative proportion of both T cell (Naive) and T cell (Cytotoxic) populations across most analyzed samples compared to normal tissue. This suggests a potential depletion or functional alteration of these key anti-tumor immune cells within the tumor microenvironment.
• Increased Regulatory T cells (Tregs): A prominent observation is the marked increase in the relative proportion of T cell (Treg) cells (represented by the dark blue segment) in almost all tumor samples. Tregs appear to constitute a significantly larger fraction of the T cell compartment in tumor tissue compared to normal tissue.
• Variable T Helper Subsets: Other T helper cell subsets such as T cell (Th1), T cell (Th17), T cell (Th2), T cell (Th22), T cell (Th9), and T cell (Tfh) are present in varying, generally smaller, proportions. While Th1 cells maintain some presence, slight increases in subsets like Th17 may be noted in some tumor samples, though the overall shift is less dramatic than for Tregs.
• Low ILCs/NK cells: Innate lymphoid cells (ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI) and NK cells consistently represent a minor fraction of the total immune cells in both normal and tumor samples. The 'unassigned' category remains low across all samples, indicating good cell type annotation resolution.

Biological Interpretation

The observed shifts in T cell subset populations in colorectal cancer are highly indicative of immune evasion and suppression mechanisms characteristic of the tumor microenvironment.

• Immune Evasion and Exhaustion: The reduction in T cell (Cytotoxic) and T cell (Naive) populations in tumor samples suggests several possibilities:
  • Exhaustion or Anergy: Cytotoxic T cells, crucial for directly killing tumor cells, may become exhausted or anergic in the chronic inflammatory and immunosuppressive tumor microenvironment, losing their anti-tumor effector functions [PubMed Search: T cell exhaustion tumor microenvironment].
  • T cell Exclusion: Tumor cells or the stromal components of the tumor microenvironment can actively exclude T cells, particularly naive T cells, from infiltrating the tumor core [PubMed Search: T cell exclusion tumor microenvironment].
  • Differentiation: Naive T cells might differentiate into other T cell subtypes upon encountering tumor antigens, though the overall reduction in the naive pool suggests a net loss of naive cells or their decreased recruitment.
• Immunosuppression by Regulatory T Cells (Tregs): The substantial increase in T cell (Treg) populations within the tumor microenvironment is a well-established hallmark of immune suppression in cancer. Tregs suppress the activity of effector T cells (like cytotoxic T cells) and other immune cells, thereby allowing tumor cells to evade immune destruction and promote tumor growth [UniProt: FOXP3 (a key Treg marker)]. Their enrichment contributes significantly to an immunosuppressive milieu, hindering effective anti-tumor responses in colorectal cancer.
• Altered T Helper Balance: While less pronounced, shifts in other T helper cell subsets could signify changes in the inflammatory landscape. For instance, an altered balance between Th1 (often anti-tumor) and Th2/Th17 (can be pro-tumorigenic or pro-inflammatory depending on context) could further impact tumor progression. Th17 cells, for example, have complex roles, sometimes promoting inflammation that supports tumor growth [PubMed Search: Th17 cells colorectal cancer].

Clinical or Translational Implications

The distinct alterations in T cell subset populations in colorectal cancer have significant clinical and translational implications:

• Prognostic Biomarkers: The relative abundance of specific T cell subsets, particularly high Treg infiltration and low cytotoxic T cell presence, can serve as prognostic biomarkers for disease progression and patient outcomes in CRC.
• Immunotherapy Response: Understanding the T cell landscape is critical for predicting and optimizing responses to immunotherapy. A high Treg-to-effector T cell ratio, as suggested by these findings, often correlates with resistance to checkpoint blockade therapies [PubMed Search: Treg PD-1 resistance].
• Targeting Immunosuppression: The pronounced increase in Tregs highlights them as a potential therapeutic target. Strategies aimed at depleting Tregs, inhibiting their function, or altering the Treg/effector T cell balance could enhance anti-tumor immunity in CRC.
• Combination Therapies: The complex interplay of T cell subsets suggests that combination therapies, potentially involving Treg depletion alongside checkpoint inhibitors or other immunomodulators, might be more effective in overcoming immune evasion in colorectal cancer.

8. Differential T Cell Subset Proportions in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots illustrating the proportional representation of specific T cell subsets (Treg, Th22, Th17, and Tfh cells) in colorectal tissue, comparing 'normal' and 'tumor' conditions. The primary goal is to identify T cell subsets that show statistically significant differences in their proportions between these two conditions, providing insights into immune microenvironment changes in colorectal cancer. The statistical significance was assessed using a p-value cutoff of 0.1, and all displayed subsets met this criterion.

Visual Summary

The box plots reveal distinct changes in the proportions of several T cell subsets when comparing tumor tissue to normal tissue:

• Treg cells: The proportion of regulatory T cells (Tregs) is significantly elevated in tumor samples (median ~8.5%) compared to normal samples (median ~3.5%), with a p-value of 0.000213. This indicates a substantial increase in these immune-suppressive cells within the tumor microenvironment.
• Th22 cells: T helper 22 (Th22) cells also show a statistically significant increase in tumor samples (median ~5%) compared to normal samples (median ~3.8%), with a p-value of 0.00366.
• Th17 cells: Similar to Tregs and Th22 cells, T helper 17 (Th17) cells demonstrate a notable increase in proportion within tumor samples (median ~9.5%) compared to normal samples (median ~4.5%), with a p-value of 0.00934.
• Tfh cells: In contrast to the other subsets, follicular helper T (Tfh) cells exhibit a decrease in proportion in tumor samples (median ~11.5%) compared to normal samples (median ~14%), with a p-value of 0.0866. While statistically significant at the applied cutoff, this p-value is higher than for the other three subsets.

Biological Interpretation

The observed shifts in T cell subset proportions provide critical insights into the immune landscape of colorectal cancer (CRC).

• Increased Tregs: Regulatory T cells (Tregs) are central mediators of immune tolerance and suppression. Their significant enrichment in the tumor microenvironment (TME) of colorectal cancer is a common hallmark of cancer progression. Tregs dampen anti-tumor immune responses, including those mediated by cytotoxic T cells, thereby promoting immune evasion and tumor growth PubMed search: Treg cancer immune evasion. This finding suggests a strongly immunosuppressive TME in CRC.
• Increased Th22 cells: Th22 cells produce IL-22, a cytokine with complex roles in immunity and tissue homeostasis. In the context of chronic inflammation and cancer, IL-22 can promote epithelial cell proliferation, survival, and tissue repair. In gastrointestinal cancers, elevated Th22 cells and IL-22 are sometimes associated with tumor growth, angiogenesis, and metastatic potential, acting in a pro-tumorigenic manner GeneCards: IL22.
• Increased Th17 cells: Th17 cells are known for producing IL-17 and are involved in inflammatory responses. Their role in cancer is often described as context-dependent, acting as a "double-edged sword." However, in many solid tumors, including CRC, an increased presence of Th17 cells and IL-17 has been linked to pro-tumorigenic effects, such as promoting tumor growth, angiogenesis, and metastasis, often by fostering a chronic inflammatory environment that supports cancer development PubMed search: Th17 colorectal cancer role.
• Decreased Tfh cells: Follicular helper T (Tfh) cells are crucial for effective humoral immunity, providing help to B cells for germinal center formation and antibody production. A decrease in Tfh cell proportion in the tumor microenvironment could indicate a compromised ability to mount a robust, sustained humoral anti-tumor response, potentially impacting the production of tumor-specific antibodies.

Collectively, these findings paint a picture of an altered immune landscape in colorectal tumors, characterized by an expansion of immune-suppressive (Treg) and potentially pro-tumorigenic inflammatory (Th22, Th17) T cell subsets, alongside a reduction in Tfh cells, which could imply a weakened humoral anti-tumor response.

Clinical or Translational Implications

The differential proportions of T cell subsets observed in colorectal cancer have several potential clinical and translational implications:

• Prognostic Biomarkers: The altered balance of T cell subsets, particularly the increased Treg/CD8 T cell ratio (implicitly suggested by increased Tregs), is often associated with poorer prognosis in CRC. These proportions could serve as prognostic biomarkers, helping to stratify patients for risk.
• Therapeutic Targets: The significant enrichment of immunosuppressive (Treg) and pro-tumorigenic inflammatory (Th22, Th17) T cell subsets presents opportunities for therapeutic intervention. Strategies aimed at depleting Tregs, inhibiting their function, or modulating the Th17/Th22 axis could enhance anti-tumor immunity and improve patient outcomes PubMed search: targeting Treg Th17 cancer therapy.
• Immunotherapy Response Prediction: The TME composition, including the balance of these T cell subsets, can influence the effectiveness of immunotherapies. For instance, a highly immunosuppressive TME with abundant Tregs might be less responsive to checkpoint blockade. Understanding these proportions could help predict responses to existing immunotherapies or guide the development of combination therapies.
• Humoral Immunity Modulation: The observed decrease in Tfh cells might suggest a need to investigate the state of B cell responses and humoral immunity in CRC. Strategies to boost Tfh cell function or improve B cell-mediated anti-tumor responses could be explored.

9. Macrophage Subset Population Analysis in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different macrophage subsets (M1, M2A, M2B, M2C, M2D) within the total macrophage population across various normal and tumor samples from Colon tissue. The data is derived from single-cell RNA-seq, and the tumor-origin cell type is identified as Intestinal Epithelial cell, consistent with Colorectal cancer. The plot allows for a comparative assessment of macrophage polarization states between healthy and cancerous colon tissues at the sample level.

Visual Summary

The stacked bar plots display the proportional distribution of five macrophage subsets: Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D) within individual samples. Samples are grouped by Condition (normal vs. tumor).

• Normal Condition: In normal colon samples (labeled B_cac), Macrophage (M2A) (orange) is generally the most abundant subtype, often dominating the macrophage population, particularly evident in samples like B_cac15, B_cac7, and B_cac14. Macrophage (M1) (dark red) is present but typically at lower levels than M2A, though its proportion can vary (e.g., B_cac10 shows a higher M1 proportion). Other M2 subtypes (M2B, M2C, M2D) constitute smaller, variable fractions.
• Tumor Condition: In tumor samples (labeled T_cac), a notable shift in macrophage composition is observed. While Macrophage (M2A) remains significant, there is a clear trend of increased Macrophage (M1) proportions in many tumor samples compared to normal, particularly prominent in T_cac3, T_cac12, T_cac6, and T_cac2, where M1 can be the dominant subtype. Concurrently, other M2 subtypes (M2B, M2C, M2D) show more pronounced and variable contributions across tumor samples (e.g., M2B is more abundant in T_cac4, T_cac13, T_cac10; M2D in T_cac9, T_cac1). This indicates a more heterogeneous macrophage landscape in the tumor microenvironment, with both pro-inflammatory (M1) and diverse anti-inflammatory/pro-tumorigenic (M2) phenotypes exhibiting variable presence across different tumor samples.

Biological Interpretation

Macrophages are critical components of the immune microenvironment, and their polarization into M1 (pro-inflammatory, anti-tumor) or M2 (anti-inflammatory, pro-tumor) phenotypes significantly influences cancer progression.

• Shift in Macrophage Polarization: The observed increase in Macrophage (M1) populations in many tumor samples is an interesting finding. M1 macrophages are typically associated with anti-tumor immunity, promoting tumor cell killing and expressing pro-inflammatory cytokines. Their heightened presence in the tumor microenvironment could represent an attempt by the host immune system to mount an anti-tumor response or reflect specific inflammatory states within certain tumors. However, the concurrent presence and increased variability of diverse M2 subtypes (M2A, M2B, M2C, M2D) suggest a complex interplay. M2 macrophages, particularly those resembling M2A, M2C, and M2D, are often associated with tumor progression, immune suppression, angiogenesis, and tissue remodeling, collectively contributing to the pro-tumorigenic tumor microenvironment (TME). Tumor-associated macrophages (TAMs) often adopt an M2-like phenotype that supports cancer growth and metastasis PubMed Search: Tumor-associated macrophages colorectal cancer M2.
• Heterogeneity in Tumor Microenvironment: The significant sample-to-sample variability in macrophage subset composition within the tumor group (T_cac) highlights the highly heterogeneous nature of the colorectal cancer TME. Some tumors might exhibit a stronger pro-inflammatory (M1-skewed) profile, while others might lean towards a more immune-suppressive or reparative (M2-skewed) environment. This heterogeneity could have implications for differential responses to immunotherapies.
• Context in Colorectal Cancer: In colorectal cancer, TAMs are known to be abundant and contribute to disease progression. While an overall M2-like polarization is often reported in established tumors, the presence of elevated M1 could signify different stages, specific immune contexts, or host responses that warrant further investigation.

Clinical or Translational Implications

The differential distribution of macrophage subsets between normal and tumor conditions, and the heterogeneity within tumor samples, carries several potential clinical implications:

• Biomarkers: The specific proportions or ratios of M1 to M2 macrophage subsets could serve as prognostic biomarkers in colorectal cancer, indicating disease aggression or potential response to therapy.
• Therapeutic Targets: Understanding the dominant macrophage phenotypes in individual tumors could inform targeted immunotherapeutic strategies. For instance, tumors with a higher M2 component might benefit from therapies aimed at re-polarizing M2 macrophages to an M1-like state or depleting M2 populations PubMed Search: macrophage re-polarization cancer therapy. Conversely, tumors with a strong M1 presence might suggest an active immune response that could be further augmented.
• Personalized Medicine: The observed inter-sample variability underscores the need for personalized approaches in cancer treatment, where the immune landscape of each patient's tumor is considered when devising therapeutic regimens. Further studies are needed to correlate these macrophage profiles with clinical outcomes and treatment responses.

10. Macrophage Subset Population Shifts in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional differences of specific macrophage subsets between normal and tumor conditions in human Colon tissue, a context relevant to Colorectal cancer. Using single-cell RNA sequencing data, the plot_box_for_celltype_population_with_signif_difference tool was employed to identify macrophage subsets that exhibit statistically significant changes in their relative abundance. The analysis focused on 'Macrophage' cells at the 'subset' taxonomic level, comparing 'tumor' condition against 'normal' as the reference. A p-value cutoff of 0.1 and a log2 fold change cutoff of 0.1 were applied to determine significance. The resulting box plots highlight specific macrophage subsets whose proportions are significantly altered in the tumor microenvironment.

Visual Summary

The box plots illustrate the celltype proportion of three macrophage subsets – Macrophage (M2A), Macrophage (M2B), and Macrophage (M2D) – across normal and tumor conditions. Each plot includes individual data points (samples) and indicates statistical significance with p-values.

• Macrophage (M2A): The proportion of Macrophage (M2A) cells is significantly *lower* in tumor samples compared to normal samples (p=0.00699). The median proportion for M2A is noticeably higher in the normal group.
• Macrophage (M2B): The proportion of Macrophage (M2B) cells is significantly *higher* in tumor samples compared to normal samples (p=0.0141). The median proportion for M2B is elevated in the tumor group.
• Macrophage (M2D): The proportion of Macrophage (M2D) cells is significantly *higher* in tumor samples compared to normal samples (p=0.0262). Similar to M2B, the median proportion for M2D is increased in the tumor group.

These results indicate a clear and statistically significant redistribution of specific macrophage subsets within the colon tissue during tumorigenesis.

Biological Interpretation

Macrophages are critical immune cells found abundantly in the tumor microenvironment (TME), where they are often referred to as tumor-associated macrophages (TAMs). Their functions are highly plastic and depend on their polarization state. Broadly, M1 macrophages are pro-inflammatory and anti-tumorigenic, while M2 macrophages are generally immunosuppressive and pro-tumorigenic, promoting tumor growth, angiogenesis, and metastasis.

The observed shifts in macrophage subsets suggest a significant re-programming of the macrophage compartment in the context of Colorectal cancer:

• Decrease in Macrophage (M2A) in tumors: M2A macrophages are typically associated with wound healing, tissue repair, and anti-inflammatory responses. Their diminished presence in the tumor context could indicate a loss of certain homeostatic or reparative functions, or a re-education of these cells into other phenotypes that better support tumor progression.
• Increase in Macrophage (M2B) and Macrophage (M2D) in tumors: Both M2B and M2D macrophage subsets are generally categorized within the broader M2-like spectrum, associated with pro-tumorigenic functions.
  • M2B macrophages can be activated by immune complexes and Toll-like receptor (TLR) agonists. While they exhibit a mixed phenotype (producing both pro- and anti-inflammatory cytokines), they are often implicated in promoting tumor growth and modulating immune responses in favor of the tumor.
  • M2D macrophages are induced by adenosine and other factors in the TME and are particularly known for promoting angiogenesis (new blood vessel formation) and immunosuppression. Their increased presence strongly suggests a microenvironment that facilitates tumor growth and helps evade anti-tumor immunity.
  • This shift towards an enrichment of M2B and M2D, coupled with a decrease in M2A, collectively points towards an immunosuppressive and pro-tumorigenic TME in Colorectal cancer. These M2-like macrophages contribute to tumor progression by secreting growth factors, promoting angiogenesis, remodeling the extracellular matrix, and suppressing anti-tumor immune responses from T cells and NK cells.

Clinical or Translational Implications

The distinct changes in macrophage subset populations observed in Colorectal cancer carry significant clinical and translational implications:

• Therapeutic Targets: The enrichment of pro-tumorigenic M2B and M2D macrophages in the tumor microenvironment identifies these specific subsets as potential therapeutic targets. Strategies aimed at depleting these cells, blocking their recruitment, or re-polarizing them towards an anti-tumorigenic M1-like phenotype could be beneficial in Colorectal cancer treatment.
• Biomarkers: The proportions of these macrophage subsets, particularly the increased M2B and M2D, could serve as prognostic biomarkers for disease progression, aggressiveness, or even response to various therapies, including immunotherapies. Monitoring these shifts could offer insights into disease dynamics.
• Immunotherapy Enhancement: Modulating the macrophage compartment could be a powerful approach to enhance the efficacy of existing immunotherapies. For instance, combining M2-targeting agents with checkpoint inhibitors might overcome resistance mechanisms mediated by TAMs and improve patient outcomes in Colorectal cancer. PubMed search: Macrophages in colorectal cancer immunotherapy

11. Ploidy Status of Intestinal Epithelial Cells in Normal and Tumor Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, Unclear) of Intestinal Epithelial cells across different samples, categorized by 'normal' and 'tumor' conditions. The Intestinal Epithelial cell type has been identified as the "Resolved tumor-origin cell type," making its ploidy profile particularly relevant for understanding cancer development. The bar plots display the proportion of each ploidy state within this specific cell type for individual samples.

Visual Summary

The visualization presents two bar plots, one for "normal" samples and one for "tumor" samples, showing the distribution of ploidy populations within Intestinal Epithelial cells.

• Normal Condition: In all observed normal samples (e.g., B_cac7, B_cac15, B_cac10), Intestinal Epithelial cells are almost exclusively Diploid (represented in orange). The Aneuploid (dark red) and Unclear (light green) populations are negligible or absent, indicating a stable genomic state in healthy tissue.
• Tumor Condition: In contrast, Intestinal Epithelial cells from tumor samples (e.g., T_cac6, T_cac8, T_cac1) exhibit a highly variable but prominent presence of Aneuploid cells.
  • Several tumor samples, such as T_cac6, T_cac8, and T_cac1, show a large majority of aneuploid Intestinal Epithelial cells, reaching over 70% in some cases.
  • The proportion of aneuploid cells varies significantly across tumor samples, ranging from substantial aneuploidy (e.g., >80% in T_cac6) to samples where diploid cells still constitute the majority (e.g., T_cac7, T_cac5, T_cac10).
  • A small 'Unclear' population is also observed in some tumor samples (e.g., T_cac6, T_cac8, T_cac14), suggesting challenges in precise ploidy determination for a minor fraction of cells.

Biological Interpretation

The observed ploidy profiles strongly align with the hallmarks of cancer, particularly genomic instability and aneuploidy.

• Normal Homeostasis: The consistent diploid state of Intestinal Epithelial cells in normal samples reflects the tightly regulated cell division and genomic integrity maintained in healthy tissues. This is the expected baseline for somatic cells.
• Tumorigenesis and Aneuploidy: The shift towards aneuploidy in Intestinal Epithelial cells from tumor samples is a critical indicator of malignancy. Aneuploidy, the condition of having an abnormal number of chromosomes, is a common feature of many cancers, including colorectal cancer, and is often associated with tumor initiation and progression [1].
  • The high prevalence of aneuploid Intestinal Epithelial cells in tumor samples supports the designation of this cell type as the "Resolved tumor-origin cell type." These cells have undergone significant chromosomal alterations, which can confer selective advantages to cancer cells, such as increased proliferation, drug resistance, and metastatic potential.
  • The heterogeneity in aneuploidy levels across different tumor samples (e.g., T_cac6 showing high aneuploidy vs. T_cac5 showing low aneuploidy) might reflect different stages of tumor progression, varying degrees of genomic instability, or inter-tumor heterogeneity characteristic of colorectal cancer [2]. Some tumors might be more chromosomally unstable than others, or the observed samples might represent different regions or subclones within a larger tumor mass.
  • The presence of some diploid Intestinal Epithelial cells even within tumor samples could indicate: a mixed population of tumor and admixed normal epithelial cells, early stages of transformation where not all cells are highly aneuploid, or specific tumor subtypes that are less aneuploid.

Clinical or Translational Implications

The findings have significant clinical and translational implications for colorectal cancer:

• Diagnostic Biomarker: The striking difference in ploidy between normal and tumor Intestinal Epithelial cells makes aneuploidy a valuable diagnostic marker. Identifying a high proportion of aneuploid Intestinal Epithelial cells can help distinguish malignant lesions from benign conditions, especially in cases where morphological assessment might be ambiguous.
• Prognostic Indicator: The degree of aneuploidy in tumor cells is often correlated with tumor aggressiveness, recurrence risk, and patient prognosis in various cancers, including colorectal cancer [3]. Samples with higher percentages of aneuploid Intestinal Epithelial cells might indicate more aggressive tumors.
• Therapeutic Target: Understanding the mechanisms leading to aneuploidy and its maintenance in cancer cells could open avenues for targeted therapies. Interventions that specifically target aneuploid cells or the pathways responsible for chromosomal instability might offer novel therapeutic strategies.

---

References:

1. Aneuploidy as a hallmark of cancer: PubMed Search: "aneuploidy cancer hallmark"
2. Genomic heterogeneity in colorectal cancer: PubMed Search: "colorectal cancer genomic heterogeneity"
3. Aneuploidy as a prognostic factor in colorectal cancer: PubMed Search: "aneuploidy colorectal cancer prognosis"

12. Remodeling of Cell-Cell Interaction Landscape in Colorectal Cancer: Normal vs. Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB, comparing normal colon tissue with colorectal tumor tissue. The focus is on interactions involving key cell types: Intestinal Epithelial cell (identified as the tumor-origin cell type), Fibroblast, Macrophage, T cell CD4+, and T cell CD8+. The goal is to identify how these interaction networks change in the presence of cancer, potentially revealing mechanisms of disease progression or immune evasion.

Visual Summary

CCI for Normal Condition

The dot plot for normal tissue reveals a rich and diverse network of cell-cell interactions.

• Key Interacting Cell Pairs: Prominent interactions are observed among T cell CD8+, T cell CD4+, and Diploid Intestinal Epithelial cells. Interactions are also noted between T cell subsets (e.g., T CD8+ | T CD4+).
• Diverse Ligand-Receptor Pairs: A wide array of ligand-receptor pairs mediate these interactions. Notable examples include:
  • Adhesion/Structural: CDH1-KLRG1, CEACAM1-CEACAM1, DSC2-DSG2A, ICAM1_integrin_aLb2_complex, ICAM3_integrin_aLb2_complex.
  • Immune Regulation/Checkpoints: HLA-E-CD94:NKG2, CD160-HVEM, CD58-CD2, VSIR_HLA-E, KLRB1_CLEC2D.
  • Prostaglandin Signaling: Multiple ProstaglandinE2 interactions with various PTGER (Prostaglandin E2 receptor) subtypes (PTGER1, PTGER2, PTGER3, PTGER4).
  • Other Signaling: APLP2-PIGR, SPP1-CD44, TNF-TNFRSF1B.
• Diploid Intestinal Epithelial Cell Interactions: These cells engage in numerous significant interactions with both CD4+ and CD8+ T cells, as well as engaging in self-interactions. Many of these interactions involve immune checkpoints (e.g., HLA-E pairs) and prostaglandin signaling, suggesting active immune surveillance and homeostatic regulation.
• Absent Cell Types: Although requested, significant interactions involving Fibroblast and Macrophage cells were not observed within the top 80 pairs displayed, implying either a lack of strong interactions with the target cell types or interactions below the applied significance thresholds.

CCI for Tumor Condition

The dot plot for tumor tissue presents a starkly simplified interaction landscape.

• Drastic Reduction: The number and diversity of significant cell-cell interactions are drastically reduced compared to normal tissue.
• Predominantly T Cell-T Cell Interactions: Only interactions among T cell CD8+ and T cell CD4+ subsets remain prominently displayed.
• Loss of Epithelial Interactions: Critically, virtually all interactions involving Intestinal Epithelial cell (specifically, "Diploid Intestinal Epi" as seen in the normal condition, implying the general epithelial compartment) are absent in the tumor context.
• Remaining Ligand-Receptor Pairs: The few remaining interactions are primarily CD58-CD2 (between T CD4+ and T CD8+), KLRB1_CLEC2D (within T CD8+ and between T CD4+ and T CD8+), and LCK_CD8_Treceptor (within T CD8+ and between T CD4+ and T CD8+). CD58-CD2 shows particularly strong interaction between T cell subsets.

Biological Interpretation

The observed shift in CCI patterns from normal to tumor profoundly reflects the dysregulation of the colorectal cancer microenvironment.

• Immune Evasion and Epithelial Transformation: The most striking finding is the near-complete loss of cell-cell interactions involving Intestinal Epithelial cell in the tumor condition. Given that Intestinal Epithelial cell is the resolved tumor-origin cell type, this suggests a critical mechanism of immune evasion. Tumor cells often downregulate surface molecules involved in immune recognition or adhesion, thereby avoiding immune surveillance. The absence of HLA-E and VSIR-HLA-E interactions with T cells, which were significant in normal tissue, is particularly indicative of altered immune checkpoint engagement, potentially allowing tumor cells to escape T cell-mediated killing.
  • HLA-E presents peptides to CD94:NKG2 receptors on T cells and NK cells, playing a role in immune tolerance; its alteration can impact immune surveillance PubMed Search: HLA-E immune evasion cancer.
• Remodeling of T Cell Compartment: While interactions involving Intestinal Epithelial cell are lost, a few T cell-T cell interactions persist in the tumor. The robust CD58-CD2 interaction, important for T cell adhesion and co-stimulation GeneCards: CD58, might reflect continued, albeit altered, intra-T cell communication or an attempt at compensatory signaling within the dysfunctional immune microenvironment. KLRB1_CLEC2D (KLRB1 is CD161) interactions, known to regulate NK cell and T cell activation PubMed Search: KLRB1 CLEC2D immune regulation, also remain, suggesting a complex interplay within the residual T cell network.
• Loss of Homeostatic Signaling: The disappearance of ProstaglandinE2 mediated interactions with epithelial cells further highlights a breakdown in normal homeostatic signaling. Prostaglandins are potent lipid mediators involved in inflammation and immunosuppression in the tumor microenvironment; their altered signaling can promote tumor growth and immune escape PubMed Search: Prostaglandin E2 cancer immunosuppression.
• Lack of Fibroblast and Macrophage Interactions: The absence of significant interactions involving Fibroblast and Macrophage cells in the displayed top pairs, despite their inclusion in the target_cells, suggests that either these cell types do not form strong direct interactions with the T cells or epithelial cells via the analyzed ligand-receptor pairs within the tumor microenvironment, or their interactions are suppressed below detection thresholds in the context of colorectal cancer. This is noteworthy given the known crucial roles of cancer-associated fibroblasts and tumor-associated macrophages in shaping the tumor microenvironment.

Clinical or Translational Implications

The profound alterations in cell-cell communication identified in colorectal cancer have significant clinical and translational implications:

• Therapeutic Targets for Immune Evasion: The observed loss of Intestinal Epithelial cell interactions with T cells, particularly those involving immune checkpoints like HLA-E, represents potential targets to overcome tumor immune evasion. Strategies aimed at restoring these interactions or targeting the compensatory pathways could enhance anti-tumor immunity.
• Modulating T Cell Function: The persistent, albeit reduced, T cell-T cell interactions, such as CD58-CD2, could be explored. Understanding how these remaining interactions influence T cell activation, exhaustion, or anergy in the tumor microenvironment may reveal opportunities to reprogram anti-tumor T cell responses.
• Biomarkers of Disease Progression: The drastic reduction in interaction complexity, particularly the disappearance of Intestinal Epithelial cell-immune cell crosstalk, could serve as a diagnostic or prognostic biomarker for colorectal cancer progression or response to therapy. Monitoring these interaction patterns might provide insights into the immune status of the tumor.
• Targeting Immunosuppressive Pathways: The altered ProstaglandinE2 signaling, evidenced by its absence in the tumor interactions, underscores its potential role in colorectal cancer. Targeting the PGE2 pathway, perhaps through COX inhibitors or receptor blockade, could be a strategy to alleviate immunosuppression and improve therapeutic efficacy.
• Investigating Absent Interactions: Further investigation into why Fibroblast and Macrophage interactions are not prominent is warranted. It could point to alternative, non-CellPhoneDB detectable interactions, or a tumor microenvironment where direct interaction via these specific ligand-receptor pairs is shut down, requiring different therapeutic approaches.

13. Condition-Specific Cell-Cell Interaction Patterns in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies significant differences in cell-cell interactions (CCIs) between normal and tumor conditions in colon tissue, focusing on interactions involving Intestinal Epithelial cells (including aneuploid tumor-origin cells), Fibroblasts, Macrophages, T cells, and other major immune and stromal cells. The dot plot visualizes the strength (color intensity) and statistical significance (dot size) of these interactions across individual samples, highlighting condition-specific communication patterns relevant to colorectal cancer.

Visual Summary

The dot plot, divided into 'normal' and 'tumor' conditions, clearly illustrates distinct cell-cell interaction landscapes.

• Normal Condition: The left panel (enclosed by the upper blue box) shows a relatively sparse pattern of interactions. While some interactions, such as those involving ProstaglandinE2_byPTGES3_PTGER4 with B cells and T cells, exhibit strong signals in certain normal samples (e.g., B_cac10, B_cac11), the overall number and intensity of significant interactions are lower compared to the tumor condition.
• Tumor Condition: The right panel (enclosed by the lower blue box) reveals a significantly denser and more robust network of cell-cell interactions. A large number of distinct ligand-receptor pairs show high interaction strength (darker red dots) and statistical significance (larger dot sizes) across the majority of tumor samples. This indicates a highly active and complex communication environment within the tumor microenvironment.
• Condition-Specific Differences: The most striking observation is the emergence of numerous new and strong interactions predominantly or exclusively within the tumor condition. These interactions frequently involve Intestinal Epithelial cell (Aneup), which are the resolved tumor-origin cells, communicating with various immune cells (T cells, Macrophages, Plasma cells) and stromal cells. This suggests a reprogramming of intercellular communication pathways that drives tumor progression and modulates the immune response.

Biological Interpretation

The dramatic shift in CCI patterns in the tumor microenvironment highlights key signaling axes that likely contribute to colorectal cancer pathogenesis. The prevalence of Intestinal Epithelial cell (Aneup) in these interactions underscores their central role as drivers or responders in the tumor communication network.

General Trends in Tumor Microenvironment

In the tumor condition, there is a marked increase in interactions, many involving the aneuploid Intestinal Epithelial cells with immune and stromal cell populations. This reflects a pro-tumorigenic milieu characterized by altered immune cell infiltration, stromal remodeling, and direct communication promoting tumor growth, survival, and immune evasion.

Key Tumor-Specific Interactions and Mechanisms

1. PPIA-BSG Signaling (Cyclophilin A - Basigin/CD147 axis):
   • Interaction: PPIA_BSG interactions are highly prominent and strong in tumor samples, particularly between Intestinal Epithelial cell (Aneup) and various immune cells, including T cell CD4+, T cell CD8+, Macrophage, and Plasma cells.
   • Mechanism: Cyclophilin A (PPIA) is a secreted immunomodulatory protein that binds to Basigin (BSG, also known as CD147 or EMMPRIN) on the cell surface. This interaction promotes various pro-tumorigenic processes, including matrix metalloproteinase (MMP) production by stromal and tumor cells, leading to extracellular matrix degradation and invasion. It also stimulates angiogenesis, inflammation, and can modulate immune cell function, often suppressing anti-tumor responses and promoting tumor growth in colorectal cancer PubMed search: PPIA BSG cancer colon.
   • Therapeutic Potential: Disrupting the PPIA-BSG axis could inhibit tumor invasion, metastasis, and reprogram the tumor immune microenvironment.
   • Therapeutic Agents: Antibodies targeting CD147/Basigin or small molecule inhibitors of PPIA are under investigation for their anti-cancer potential.
2. CEACAM-Mediated Interactions (Carcinoembryonic Antigen-related Cell Adhesion Molecules):
   • Interaction: Interactions like CEACAM5_CEACAM1 and CEACAM6_CEACAM1/CEACAM6 are highly active in tumor samples, primarily between Intestinal Epithelial cell (Aneup) and T cell CD4+, T cell CD8+, and Macrophages.
   • Mechanism: CEACAMs are cell adhesion molecules whose expression is often dysregulated in cancer. CEACAM5 and CEACAM6 are overexpressed in colorectal cancer and play roles in cell adhesion, proliferation, survival, and immune evasion. They can interact with immune cells to suppress anti-tumor immunity by inhibiting T cell activation and promoting myeloid-derived suppressor cell functions GeneCards: CEACAM5, GeneCards: CEACAM6.
   • Therapeutic Potential: Targeting CEACAMs can interfere with tumor cell growth, metastasis, and potentially reverse immune suppression.
   • Therapeutic Agents: Monoclonal antibodies against CEACAM5 (e.g., labetuzumab, or next-generation anti-CEACAM5 antibodies under development) are being explored for therapeutic applications in CRC.
3. Prostaglandin E2 (PGE2) Signaling:
   • Interaction: While present in normal samples, ProstaglandinE2_byPTGES3_PTGER2/PTGER4 interactions, especially those involving Intestinal Epithelial cell (Aneup), show prominent activity in the tumor context.
   • Mechanism: Prostaglandin E2 (PGE2), synthesized by enzymes like PTGES3, acts through its receptors (PTGERs, or EP receptors) to mediate various cellular processes. In colorectal cancer, PGE2 signaling is often upregulated and promotes cell proliferation, survival, angiogenesis, and immune suppression (e.g., inhibiting NK cell activity and promoting Treg differentiation). It is a key mediator of inflammation-associated cancer PubMed search: PGE2 PTGER colorectal cancer.
   • Therapeutic Potential: Inhibiting PGE2 production or blocking its receptors could be a valuable strategy to suppress tumor growth and modulate the immune response.
   • Therapeutic Agents: Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (e.g., celecoxib) reduce PGE2 synthesis. EP receptor antagonists are also under development.
4. Other Notable Interactions in Tumor:
   • TYROBP-CD44 (Intestinal Epithelial cell (Aneup) - Macrophage, T cell CD4+): CD44 is a known cancer stem cell marker and promotes tumor progression, metastasis, and drug resistance. Targeting CD44 could address tumor stemness.
   • APP-CD74 (Intestinal Epithelial cell (Aneup) - T cell CD4+, T cell CD8+): Both APP and CD74 play roles in inflammation and cancer, potentially modulating T cell responses and tumor survival.
   • LPAR2-ADGRE5 (Intestinal Epithelial cell (Aneup) - Plasma cell): LPAR2 mediates pro-tumorigenic effects of LPA, while ADGRE5 (CD97) is implicated in tumor progression.
   • IGF1-integrin_a6b4_complex (Plasma cell - Intestinal Epithelial cell (Aneup)): IGF1 signaling promotes growth and survival, and integrin α6β4 is crucial for epithelial cell adhesion and migration, linked to invasion and metastasis in epithelial cancers. Targeting IGF1R or integrin α6β4 could disrupt these pro-tumorigenic signals. GeneCards: IGF1

Clinical or Translational Implications

The identified tumor-specific cell-cell interactions offer promising avenues for therapeutic intervention in colorectal cancer.

• Targeting Immunomodulatory Axes: Interacting pathways like PPIA-BSG and CEACAMs between tumor cells and immune cells represent potential targets to overcome immune suppression and enhance anti-tumor immunity. Therapeutic antibodies against CD147/Basigin or CEACAMs could be explored as single agents or in combination with existing immunotherapies.
• Disrupting Pro-tumorigenic Signaling: Inhibiting PGE2 signaling, either through COX-2 inhibitors or EP receptor antagonists, could reduce tumor growth, inflammation, and immune evasion. Targeting the IGF1-integrin axis or CD44 could address tumor proliferation, metastasis, and cancer stem cell properties.
• Biomarker Development: The identified ligand-receptor pairs, particularly those exclusive to the tumor microenvironment, could serve as biomarkers for patient stratification, response prediction, or monitoring disease progression.
• Combination Therapies: The complexity of the tumor microenvironment suggests that combination therapies, targeting multiple interaction pathways simultaneously, might be more effective than single-agent approaches. For instance, combining an immune checkpoint inhibitor with a therapy that disrupts tumor-immune cell communication (e.g., anti-CEACAM or anti-CD147) could yield synergistic effects.

14. Condition-Specific Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) involving specific immune and stromal cell types, as well as Intestinal Epithelial cells (the resolved tumor-origin cell type), in human Colon tissue. The focus is on interactions mediated by genes related to immune checkpoints and cell cycle pathways. The aim is to identify differentially significant interactions between 'normal' and 'tumor' conditions. The plot_dot_for_cci_with_signif_difference tool was used to visualize these interactions across individual samples, highlighting both interaction strength (color intensity) and statistical significance (dot size). The target cell types included Intestinal Epithelial cells (both diploid and aneuploid populations identified), Fibroblasts, Macrophages, T cells (CD4+, CD8+), B cells, Myeloid cells, Mast cells, Stromal cells, and Endothelial cells.

Visual Summary

The dot plot clearly illustrates a profound shift in the cell-cell interaction landscape between normal and tumor colon tissues.

• Normal Condition: In the normal samples (left panel), significant cell-cell interactions are relatively sparse. The interactions observed are primarily between immune cells (e.g., T cell CD8+ with T cell CD8+, B cell with T cell CD4+) and some involve diploid Intestinal Epithelial cells. The overall scaled log strength and significance (dot size) are generally lower compared to the tumor condition.
• Tumor Condition: The tumor samples (right panel) display a dramatically increased number and strength of significant cell-cell interactions. Almost all tumor samples exhibit extensive and robust interactions. A striking feature is the frequent involvement of aneuploid Intestinal Epithelial cells (Ent.Epi (Aneuploid)) as one of the interacting partners. These tumor cells interact extensively with various immune cells, particularly Macrophages, T cells (CD4+ and CD8+), and also show homophilic interactions among themselves. The high intensity of the red color and larger dot sizes indicate stronger and more statistically significant interactions in the tumor microenvironment.
• Differential Patterns: The most significant differences are seen in interactions that become highly prevalent or strengthened in the tumor context, suggesting unique communication axes that emerge or are dysregulated during carcinogenesis. While some interactions (e.g., ProstaglandinE2 related) appear in both conditions, their specific cell partners or overall prevalence differ. The shift from a more quiescent, immune-homeostatic interaction pattern in normal tissue to a highly dynamic and complex pro-tumorigenic interaction network in the tumor is evident.

Biological Interpretation

The analysis reveals distinct patterns of cell-cell communication associated with colorectal cancer progression, particularly highlighting the extensive involvement of aneuploid tumor cells and their interactions with the immune and stromal compartments.

Interactions in Normal Condition

In healthy colon tissue, observed interactions generally reflect normal immune surveillance and tissue homeostasis.

• ProstaglandinE2_byPTGES3_PTGER4 -- T CD8+ | T CD8+: This interaction involves Prostaglandin E2 (PGE2), synthesized by PTGES3, signaling through its receptor PTGER4 (EP4) on CD8+ T cells. In a healthy context, PGE2 can play roles in modulating T cell responses to maintain immune tolerance or regulate inflammation.
• PPIA_BSG -- T CD8+ | T CD8+: The interaction between Cyclophilin A (PPIA) and CD147 (BSG) on CD8+ T cells may contribute to T cell activation, proliferation, and matrix metalloproteinase induction, important for immune cell function and tissue remodeling in normal physiology.
• BTLA_TNFRSF14 -- B cell | T CD4+: This represents a canonical immune checkpoint interaction. BTLA (B and T Lymphocyte Attenuator) is an inhibitory receptor, and TNFRSF14 (HVEM, Herpesvirus Entry Mediator) is its ligand. This interaction is crucial for maintaining peripheral T cell tolerance and preventing excessive immune activation in healthy tissues.

Interactions in Tumor Condition

The tumor microenvironment (TME) is characterized by a high density of complex interactions, many involving aneuploid Intestinal Epithelial cells. These interactions often promote tumor growth, immune evasion, and stromal remodeling. Key examples include:

1. CEACAM5_CEACAM6 -- Ent.Epi (Aneuploid) | Ent.Epi (Aneuploid) & CEACAM5_CEACAM1 -- Ent.Epi (Aneuploid) | Ent.Epi (Aneuploid)
   • Signaling Pathways/Mechanisms: Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), particularly CEACAM5 and CEACAM6, are often overexpressed in colorectal cancer. They mediate both homophilic (e.g., CEACAM5-CEACAM5) and heterophilic (e.g., CEACAM5-CEACAM6 or CEACAM5-CEACAM1) interactions. These interactions promote tumor cell aggregation, survival, and proliferation by activating intracellular signaling pathways such as PI3K/Akt and ERK. CEACAM1 also plays roles in immune suppression by interacting with inhibitory receptors on immune cells. The strong presence of these interactions suggests enhanced tumor cell cohesion and intra-tumoral signaling networks.
   • Therapeutic Potential: Disrupting CEACAM-mediated cell adhesion and signaling could inhibit tumor growth, prevent metastasis, and potentially enhance anti-tumor immune responses.
   • Therapeutic Agents: Monoclonal antibodies targeting CEACAM5 (e.g., Labetuzumab, Tusamitamab ravtansine) and CEACAM6 are under clinical investigation for colorectal and other cancers. CAR-T cell therapies targeting CEACAM5 are also being explored. [PubMed Search: "CEACAM5 therapy colorectal cancer" PubMed Search]
2. CD52_SIGLEC10 -- Ent.Epi (Aneuploid) | T CD4+ / T CD8+
   • Signaling Pathways/Mechanisms: CD52 is a cell surface glycoprotein, and SIGLEC10 (Sialic acid-binding immunoglobulin-like lectin 10) is an inhibitory immune checkpoint receptor expressed on various immune cells, including T cells. The interaction between CD52 on aneuploid Intestinal Epithelial cells (tumor cells) and SIGLEC10 on T cells delivers inhibitory signals, suppressing T cell activation, proliferation, and effector functions. This is a significant mechanism of immune evasion employed by tumor cells.
   • Therapeutic Potential: Blocking this inhibitory axis could unleash anti-tumor T cell responses, similar to other immune checkpoint blockade strategies.
   • Therapeutic Agents: Therapies targeting SIGLEC10 or its ligands are an active area of preclinical and early clinical investigation in immuno-oncology, aiming to enhance anti-tumor immunity. [PubMed Search: "SIGLEC10 immune checkpoint cancer" PubMed Search]
3. APP_CD74 -- Ent.Epi (Aneuploid) | Mac
   • Signaling Pathways/Mechanisms: Amyloid Precursor Protein (APP) is involved in cell adhesion and signaling. CD74, the invariant chain of MHC class II, can also function as a cell surface receptor activating pathways like NF-κB and MAPK, promoting cell survival, proliferation, and migration. This interaction between aneuploid Intestinal Epithelial cells and macrophages likely mediates pro-tumorigenic inflammation, influences macrophage polarization (e.g., towards an M2-like phenotype), and contributes to tumor progression in the TME.
   • Therapeutic Potential: Inhibiting CD74 signaling could reduce tumor cell proliferation and survival, and modulate the pro-tumor functions of tumor-associated macrophages.
   • Therapeutic Agents: Anti-CD74 monoclonal antibodies (e.g., Milatuzumab) have been developed for hematological malignancies and are being explored for solid tumors. [GeneCards: "CD74" GeneCards]
4. ProstaglandinE2_byPTGES3_PTGER4 -- Ent.Epi (Aneuploid) | Mac
   • Signaling Pathways/Mechanisms: PGE2, synthesized by PTGES3 in tumor or stromal cells, signals through its EP4 receptor (PTGER4) on macrophages and other immune cells. In the TME, this axis promotes chronic inflammation, angiogenesis, and immunosuppression. PGE2 can drive M2-like polarization of macrophages, leading to the secretion of pro-tumorigenic factors and suppression of anti-tumor T cell responses, thereby supporting tumor growth and immune escape.
   • Therapeutic Potential: Inhibiting PGE2 synthesis or blocking its EP4 receptor could reduce tumor-promoting inflammation and immunosuppression, potentially sensitizing tumors to other therapies.
   • Therapeutic Agents: Non-steroidal anti-inflammatory drugs (NSAIDs) like celecoxib, which inhibit COX enzymes involved in PGE2 production, have been studied for cancer prevention and adjuvant therapy. Selective EP4 receptor antagonists are under investigation in preclinical and clinical studies for various cancers. [PubMed Search: "EP4 antagonist colorectal cancer" PubMed Search]
5. NAMP_NOX2_complex -- Ent.Epi (Aneuploid) | Mac
   • Signaling Pathways/Mechanisms: Nicotinamide phosphoribosyltransferase (NAMPT, also known as visfatin) is a key enzyme in NAD+ biosynthesis, often highly expressed by tumor cells and promoting tumor growth. The NOX2 complex in macrophages generates reactive oxygen species (ROS). The interaction or coordinated activity between NAMPT (from tumor cells) and NOX2 (in macrophages) can contribute to oxidative stress and inflammatory responses in the TME, supporting tumor cell proliferation, survival, and influencing immune cell functions.
   • Therapeutic Potential: Targeting NAMPT could disrupt tumor cell metabolism and NAD+ dependency. Modulating NOX2 activity could reduce pro-tumorigenic oxidative stress and inflammation.
   • Therapeutic Agents: NAMPT inhibitors (e.g., FK866, KPT-9274) have shown anti-tumor activity in preclinical models and are in clinical trials. NOX inhibitors are also being explored. [GeneCards: "NAMPT" GeneCards]

Clinical or Translational Implications

The differential cell-cell interactions identified between normal and tumor conditions, particularly those involving aneuploid Intestinal Epithelial cells, represent promising avenues for therapeutic intervention in colorectal cancer. Targeting these specific communication axes could offer strategies to inhibit tumor progression, overcome immune evasion, and modify the pro-tumorigenic microenvironment.

• Immune Checkpoint Modulation: The prominence of the CD52-SIGLEC10 axis in tumor samples highlights a novel immune checkpoint interaction. Developing antibodies to block SIGLEC10 or its ligands could be a strategy to reactivate anti-tumor T cell responses, complementing existing PD-1/PD-L1 or CTLA-4 blockade. The BTLA-HVEM axis also represents an opportunity for immune modulation, although it appears less prominent in the tumor-specific differential context here.
• Targeting Tumor-Stromal Interactions: Interactions like APP-CD74 and ProstaglandinE2-PTGER4 between tumor cells and macrophages underscore the critical role of the myeloid compartment in supporting tumor growth and immunosuppression. Interventions that disrupt these interactions or re-educate tumor-associated macrophages (TAMs) could significantly impede tumor progression.
• Inhibiting Pro-survival and Proliferation Pathways: Overexpressed CEACAMs (CEACAM5, CEACAM6) mediating tumor cell-tumor cell and tumor cell-immune cell interactions are well-established targets. Therapies aimed at blocking these adhesion molecules could directly inhibit tumor cell proliferation, survival, and metastasis. Similarly, targeting NAMPT could disrupt tumor metabolism.
• Combination Therapies: Given the complexity of the TME, combinatorial strategies are likely to be most effective. For instance, combining immune checkpoint inhibitors (e.g., anti-SIGLEC10) with agents that modulate the TME (e.g., EP4 antagonists or NAMPT inhibitors) or target tumor cell survival (e.g., anti-CEACAM antibodies) could achieve synergistic anti-tumor effects.

Further validation of these interactions in larger patient cohorts and functional studies are warranted to fully elucidate their roles in colorectal cancer and to develop precision therapies.

15. Surfaceome Marker Expression in Intestinal Epithelial Cells of Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of surfaceome markers within Intestinal Epithelial cell subclusters from both normal and tumor conditions. The primary goal is to identify condition-specific surface markers, distinguishing between established therapeutic targets and those with potential, and to describe their associated biological mechanisms and therapeutic relevance in the context of colorectal cancer. The analysis leveraged single-cell RNA-seq data from human Colon tissue, focusing on the 'Intestinal Epithelial cell' population, which has been identified as the tumor-origin cell type. Cell subclusters, denoted by _cac groups (e.g., Diploid T_cac and T_cac), are presented under their respective conditions (normal or tumor), with dot size representing the fraction of cells expressing the marker and color intensity indicating the mean expression level.

Visual Summary

The dot plot effectively distinguishes between Intestinal Epithelial cell subclusters predominantly found in normal tissue versus those associated with tumor tissue.

• Normal-Associated Intestinal Epithelial Cells (Top Panel - "normal"): Several Diploid T_cac subclusters (e.g., Diploid T_cac3, Diploid T_cac11, Diploid T_cac8) exhibit higher expression of specific surface markers under the "normal" condition. These clusters generally show lower expression for most markers in the "tumor" context. Markers such as MUC4, SPINT2, CDHR5, CLDN7, and CDH1 show notable expression in these normal-like epithelial cells. The overall expression intensity for most markers in the normal condition is moderate compared to the tumor counterpart.
• Tumor-Associated Intestinal Epithelial Cells (Bottom Panel - "tumor"): A distinct group of Intestinal Epithelial cell subclusters (T_cac3, T_cac11, T_cac6, etc., and some B_cac groups) demonstrates a striking upregulation of numerous surfaceome markers in the "tumor" condition. These subclusters, likely representing the neoplastic Intestinal Epithelial cells, show high mean expression (darker red dots) and a high fraction of expressing cells (larger dot sizes) for many markers. Key markers highly expressed in these tumor-associated cells include CEACAM5, CD63, APP, BSG (CD147), AREG, CD151, CD46, PMEPA1, TMEM123, CD9, and TSPAN8. This clear differential expression highlights potential targets specifically enriched on tumor cells.
• Differential Expression Patterns: The red boxes in the plot clearly delineate clusters and markers that are strongly upregulated in the tumor condition. This strong upregulation of numerous surface proteins in the tumor microenvironment suggests a significant alteration in cell surface biology, likely contributing to tumor growth, invasion, and immune evasion.

Biological Interpretation

The observed differential expression of surfaceome markers in Intestinal Epithelial cells between normal and tumor conditions provides critical insights into colorectal cancer biology. The Diploid T_cac groups are inferred to represent healthy or less pathologically altered epithelial cells, while the T_cac and B_cac groups showing high expression in the tumor condition likely correspond to the aneuploid, tumor-origin Intestinal Epithelial cells identified in the data context.

Tumor-Associated Intestinal Epithelial Cell Markers

1. CEACAM5 (Carcinoembryonic antigen-related cell adhesion molecule 5)
   • Pathways/Mechanisms: A GPI-anchored cell surface glycoprotein, CEACAM5 is a classic tumor-associated antigen widely overexpressed in adenocarcinomas, including colorectal cancer. It mediates cell adhesion, promotes cell proliferation, survival, and can modulate immune responses, contributing to immune evasion. Its overexpression is often linked to advanced disease and poor prognosis.
   • Therapeutic Agents: Established therapeutic target.
     • Antibody-drug conjugates (ADCs): Several ADCs targeting CEACAM5 are under clinical investigation for CRC, leveraging its high and specific expression on tumor cells to deliver cytotoxic payloads. PubMed search: CEACAM5 antibody-drug conjugate colorectal cancer
     • Monoclonal antibodies and CAR T-cell therapies are also being explored. GeneCards: CEACAM5
2. AREG (Amphiregulin)
   • Pathways/Mechanisms: A ligand for the Epidermal Growth Factor Receptor (EGFR), AREG activates downstream signaling pathways (e.g., MAPK, PI3K/Akt) that drive cell proliferation, survival, and migration. Upregulation of AREG in CRC often contributes to tumor growth and can influence sensitivity or resistance to EGFR-targeted therapies.
   • Therapeutic Agents: Established therapeutic target (indirectly via EGFR).
     • EGFR inhibitors: While AREG itself isn't directly targeted, its increased expression indicates activation of the EGFR pathway. Anti-EGFR monoclonal antibodies (e.g., Cetuximab, Panitumumab) are standard treatments for metastatic CRC in patients with WT KRAS/NRAS, and AREG levels can be prognostic for response. PubMed search: AREG EGFR colorectal cancer
     • GeneCards: AREG
3. BSG (Basigin, CD147)
   • Pathways/Mechanisms: A transmembrane glycoprotein involved in cell adhesion, migration, and invasion. BSG is a key inducer of matrix metalloproteinases (MMPs), which degrade the extracellular matrix, facilitating tumor cell invasion and metastasis. It also plays a role in tumor metabolism by regulating lactate transport.
   • Therapeutic Agents: Less well-characterized marker with potential as therapeutic target.
     • Monoclonal antibodies: Anti-CD147 antibodies have shown anti-tumor activity in preclinical models. Its role in MMP activation and metabolism makes it an attractive target. PubMed search: CD147 cancer therapy
     • GeneCards: BSG
4. CD63 (Cluster of Differentiation 63)
   • Pathways/Mechanisms: A tetraspanin protein involved in regulating cell adhesion, motility, and exosome biogenesis and secretion. Exosomes containing CD63 play a role in intercellular communication, contributing to tumor progression, metastasis, and modulating the tumor microenvironment.
   • Therapeutic Agents: Less well-characterized marker with potential as therapeutic target.
     • Due to its role in exosome biology, targeting CD63 could modulate tumor-stromal interactions and metastasis. Investigations into specific inhibitors or antibody-based therapies are ongoing. GeneCards: CD63
5. CD151 (Cluster of Differentiation 151)
   • Pathways/Mechanisms: Another tetraspanin that complexes with integrins (e.g., α3β1, α6β1) and growth factor receptors. It critically modulates integrin-dependent cell adhesion, migration, invasion, and signaling, all of which are essential for cancer progression and metastasis.
   • Therapeutic Agents: Less well-characterized marker with potential as therapeutic target.
     • Preclinical studies have explored anti-CD151 antibodies to inhibit tumor cell invasion and metastasis. GeneCards: CD151
6. CD46 (Complement Regulatory Protein)
   • Pathways/Mechanisms: A cell surface protein that protects host cells from complement-mediated lysis. Upregulation in cancer cells, including CRC, allows them to evade immune destruction by inhibiting complement activation. It also participates in cell proliferation and survival.
   • Therapeutic Agents: Less well-characterized marker with potential as therapeutic target.
     • Antibodies targeting CD46 are being investigated for their potential to enhance anti-tumor immunity by blocking complement evasion or as direct cytotoxic agents. PubMed search: CD46 cancer therapy
     • GeneCards: CD46

Normal-Associated Intestinal Epithelial Cell Markers

Markers like MUC4, SPINT2, CDHR5, CLDN7, and CDH1 show higher expression in the Diploid T_cac groups within the normal condition. These likely represent proteins essential for maintaining normal intestinal epithelial function, barrier integrity, and tissue homeostasis. While some like MUC4 and CDH1 can have complex roles in cancer, their predominant expression in the normal context here makes them markers of a healthy epithelial state. For example:

• SPINT2 (Serine peptidase inhibitor, Kunitz type 2): Inhibits serine proteases, notably matriptase and hepsin, which activate HGF/c-Met signaling. In normal epithelium, SPINT2 is crucial for maintaining homeostasis and can act as a tumor suppressor by regulating growth factor activation.
  • GeneCards: SPINT2
• CDHR5 (Cadherin related family member 5): A specific intestinal protocadherin-like cell adhesion molecule crucial for maintaining intestinal epithelial barrier function. Its presence highlights normal epithelial integrity.
  • GeneCards: CDHR5

Clinical or Translational Implications

The identification of highly expressed surfaceome markers on tumor-associated Intestinal Epithelial cells has direct clinical implications for colorectal cancer:

1. Therapeutic Target Prioritization: Markers like CEACAM5 and AREG (via EGFR) are validated therapeutic targets, suggesting that specific strategies like ADCs or EGFR inhibitors could be highly effective for patients whose tumors express these markers strongly. This provides a data-driven approach for identifying patient cohorts likely to respond to existing or developing therapies.
2. Novel Drug Development: Markers such as CD63, BSG (CD147), CD151, and CD46, which are highly upregulated in tumor cells but less well-characterized as direct therapeutic targets in CRC, represent promising candidates for novel drug development. These could be pursued through monoclonal antibodies, bispecific antibodies, ADCs, or CAR T-cell therapies. Understanding their specific roles in tumor progression (e.g., immune evasion, metastasis, metabolism) will guide the design of targeted interventions.
3. Biomarker Discovery: The differentially expressed surface markers can serve as diagnostic, prognostic, or predictive biomarkers. For instance, high expression of CEACAM5 or AREG could indicate disease presence, aggressiveness, or likelihood of response to specific treatments. Markers highly expressed in normal cells could potentially be used to monitor the health of the surrounding tissue or to distinguish normal from malignant cells during surgery.
4. Minimizing Off-Target Toxicity: Focusing on surfaceome markers specifically enriched in tumor-associated Intestinal Epithelial cells (as seen in the tumor condition clusters) helps in designing therapies with improved specificity, potentially reducing off-target effects on healthy tissues.

This analysis provides a valuable starting point for experimental validation of these markers, both in vitro and in vivo, to confirm their functional roles and therapeutic utility in colorectal cancer.

16. Fibroblast Condition-Specific Surfaceome Markers in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers differentially expressed in various fibroblast subpopulations across normal and tumor conditions within the Colon tissue. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for five identified fibroblast clusters: B_cac14, T_cac8, T_cac1, T_cac3, and T_cac2. The objective is to highlight condition-specific markers for Fibroblasts, interpret their biological roles, and assess their potential as therapeutic targets in the context of colorectal cancer. The analysis specifically focused on surfaceome markers, with at most 40 markers identified per condition based on predefined scoring and fold change cutoffs.

Visual Summary

The dot plot clearly illustrates distinct expression profiles for fibroblast subpopulations between normal and tumor conditions.

• Fibroblast Heterogeneity: Five fibroblast clusters (B_cac14, T_cac8, T_cac1, T_cac3, T_cac2) are identified, suggesting functional diversity. T_cac2 is the most abundant cluster (244 cells), followed by T_cac3 (141 cells), T_cac1 (90 cells), B_cac14 (48 cells), and T_cac8 (32 cells).
• Normal-Associated Markers: In the normal condition (left panel), clusters B_cac14 and T_cac8 display high expression and prevalence of markers such as EMP2, FCGRT, LRP1, PLPP3, PAM, PROCR, CD9, PRNP, IFNGR1, and TMEM9. These markers are largely diminished or absent in the tumor condition, indicating a shift in fibroblast phenotype.
• Tumor-Associated Markers (CAF Signature): In the tumor condition (right panel), a strong signature of cancer-associated fibroblast (CAF) markers emerges across several clusters, particularly T_cac8, T_cac1, T_cac3, and T_cac2.
  • Highly expressed and prevalent markers in tumor fibroblasts include THY1, MXRA8, F2R, MYADM, PTTG1IP, ITGA1, PDGFRB, TSPAN3, ANTXR1, CDH11, NECTIN2, MMP14, HM13, F3, ITGAV, TMEM204, TMEM123, TMEM30A, LTBR, PDLIM5, IFNGR2, FAT1, ICAM1, and EDNRA.
  • Many of these, such as THY1, PDGFRB, ITGA1, ITGAV, F3, F2R, CDH11, and MMP14, show very high mean expression and are present in a large fraction of cells in multiple tumor-associated fibroblast clusters, indicating robust activation and widespread presence of a pro-tumorigenic fibroblast phenotype.
• Differential Activation: While B_cac14 and T_cac8 show prominent expression of "normal" markers, T_cac8 also exhibits strong expression of tumor-associated markers, suggesting it might represent a population that transitions or gets activated in the tumor microenvironment. T_cac1, T_cac3, and T_cac2 are largely quiescent in the normal state but become highly activated in the tumor.

Biological Interpretation

The observed shift in fibroblast surfaceome markers between normal and tumor conditions points to the profound reprogramming of fibroblasts into cancer-associated fibroblasts (CAFs) within the colorectal cancer tumor microenvironment (TME). These distinct fibroblast subpopulations likely play diverse, yet critical, roles in supporting tumor progression.

Markers Characteristic of Normal Fibroblasts:

Markers highly expressed in normal fibroblast clusters (B_cac14, T_cac8) suggest roles in maintaining tissue homeostasis and regulating baseline physiological functions.

• EMP2 (Endothelial Cell-Specific Molecule 2): In fibroblasts, EMP2 can modulate cell proliferation, adhesion, and migration. In normal colon tissue, it might contribute to the stable organization of the extracellular matrix (ECM) and maintain a quiescent fibroblast state. GeneCards: EMP2
• FCGRT (Fc Fragment Of IgG Receptor And Transporter): Commonly known as FcRn, this receptor is crucial for IgG recycling and maintaining IgG homeostasis. Its presence on some normal fibroblasts might indicate a role in immune surveillance, antigen presentation, or local immunomodulation in a non-inflammatory setting. GeneCards: FCGRT

Markers Characteristic of Tumor-Associated Fibroblasts (CAFs):

The marked upregulation of specific surfaceome markers in tumor fibroblast clusters (T_cac8, T_cac1, T_cac3, T_cac2) highlights their activation and pro-tumorigenic functions, which are critical in colorectal cancer.

• THY1 (CD90): This glycoprotein is a well-established marker for activated fibroblasts and CAFs.
  • Signaling Pathways: THY1 interacts with integrins and can activate downstream signaling pathways such as FAK, Src, and Rho GTPases, influencing cell adhesion, migration, and proliferation. It is also implicated in TGF-β and Wnt signaling pathways.
  • Role in TME: THY1-positive CAFs promote ECM remodeling, angiogenesis, and suppress anti-tumor immune responses, contributing to tumor growth, invasion, and metastasis in colorectal cancer. GeneCards: THY1
• PDGFRB (Platelet-Derived Growth Factor Receptor Beta): A receptor tyrosine kinase highly expressed on activated fibroblasts.
  • Signaling Pathways: Upon binding to PDGF ligands, PDGFRB activates critical pro-survival and proliferative pathways including PI3K/Akt, MAPK, and STAT pathways.
  • Role in TME: PDGFRB signaling is a major driver of CAF proliferation, differentiation, and survival. It promotes desmoplasia (dense fibrotic stroma), angiogenesis, and the recruitment of immune suppressive cells, forming a supportive niche for tumor cells in colorectal cancer. GeneCards: PDGFRB
• MMP14 (Matrix Metalloproteinase 14): Also known as MT1-MMP, this is a membrane-anchored matrix metalloproteinase.
  • Signaling Pathways: MMP14 directly degrades ECM components (e.g., collagen, fibronectin) and activates other MMPs (like pro-MMP2), facilitating ECM remodeling. It can also cleave non-ECM substrates, releasing growth factors or activating receptors.
  • Role in TME: CAFs highly express MMP14, which is crucial for creating proteolytic pathways within the dense stroma, allowing tumor cells to invade surrounding tissues and metastasize. It also promotes angiogenesis and influences the bioavailability of growth factors. GeneCards: MMP14
• F3 (Coagulation Factor III, Tissue Factor): The primary initiator of the extrinsic coagulation cascade.
  • Signaling Pathways: Beyond coagulation, F3 (via its complex with FVIIa) can activate protease-activated receptors (PARs), particularly PAR2, on cell surfaces, leading to downstream signaling involved in cell proliferation, migration, and angiogenesis.
  • Role in TME: High expression of F3 on CAFs contributes to the procoagulant state often associated with cancer, increasing the risk of thrombosis. More importantly, F3 signaling promotes tumor growth, angiogenesis, and metastasis by fostering an inflammatory and immunosuppressive microenvironment. GeneCards: F3
• ITGAV (Integrin Subunit Alpha V): This integrin subunit forms heterodimers (e.g., with ITGB1, ITGB3, ITGB5) that bind to a broad range of ECM proteins, including fibronectin and vitronectin.
  • Signaling Pathways: Integrin αV signaling activates focal adhesion kinase (FAK), Src, and PI3K/Akt pathways, crucial for cell adhesion, migration, and survival. Notably, integrin αV-containing complexes (e.g., αVβ6, αVβ8) are critical for activating latent TGF-β, a key pro-fibrotic and immunosuppressive cytokine in the TME.
  • Role in TME: Upregulation of ITGAV on CAFs enhances their ability to interact with the altered ECM, promotes cell migration and invasion, and is central to the TGF-β activation loop, driving fibrosis and immune evasion in colorectal cancer. GeneCards: ITGAV
• F2R (Coagulation Factor II Receptor, Thrombin Receptor, PAR1): A G protein-coupled receptor activated by thrombin.
  • Signaling Pathways: Activation of F2R by thrombin initiates diverse intracellular signaling cascades, including MAPK, PI3K/Akt, and Rho GTPases, leading to changes in cell proliferation, migration, and gene expression.
  • Role in TME: Thrombin levels are often elevated in the TME. F2R activation on CAFs can promote their activation, proliferation, and secretion of pro-tumorigenic factors, contributing to angiogenesis, inflammation, and immunosuppression, thereby facilitating colorectal cancer progression. GeneCards: F2R

The observed distinct fibroblast clusters indicate functional specialization. While B_cac14 and T_cac8 may represent homeostatic or less activated states in normal tissue, the widespread expression of CAF markers across T_cac8, T_cac1, T_cac3, and T_cac2 in the tumor suggests that different fibroblast subtypes are recruited and activated to perform diverse roles in tumor progression.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers on fibroblasts offers significant potential for diagnostic, prognostic, and therapeutic strategies in colorectal cancer.

1. Diagnostic and Prognostic Biomarkers: The differential expression of markers like THY1, PDGFRB, MMP14, F3, and ITGAV in tumor-associated fibroblasts could serve as biomarkers for detecting cancer, monitoring disease progression, or predicting patient outcomes in colorectal cancer. These markers could be assessed via immunohistochemistry, flow cytometry, or advanced imaging techniques on tissue biopsies or circulating cells.
2. Therapeutic Targets for CAF Depletion/Reprogramming: Targeting CAFs directly or reprogramming their pro-tumorigenic functions represents a promising strategy.
   • PDGFRB: Its role in CAF activation makes it an attractive target. Tyrosine kinase inhibitors (TKIs) like imatinib or sunitinib, which target PDGFR, are already used in other cancers. Repurposing or developing more specific PDGFRB inhibitors could modulate CAF activity in colorectal cancer.
   • MMP14: Inhibiting MMP14 could reduce ECM degradation and tumor invasion. While broad-spectrum MMP inhibitors have faced challenges in clinical trials due to side effects, more specific MMP14 inhibitors are under investigation.
   • ITGAV: Given its role in TGF-β activation and CAF-ECM interactions, targeting ITGAV using antibodies or small molecule inhibitors could disrupt key pro-tumorigenic pathways. Cilengitide, an αVβ3/αVβ5 inhibitor, has been evaluated in clinical trials for other cancers, highlighting the feasibility of integrin-based therapies.
   • THY1, F3, F2R: These markers are also emerging as potential targets. Antibodies or small molecules designed to block their function or signaling pathways could attenuate CAF-mediated immunosuppression, angiogenesis, and tumor growth. For instance, inhibitors of PAR1 (F2R) are being explored for their anti-tumor potential.
3. Combination Therapies: Targeting CAFs in combination with conventional chemotherapy, radiation, or immunotherapy could synergistically improve treatment efficacy by overcoming stromal-mediated resistance mechanisms and enhancing anti-tumor immune responses in colorectal cancer. For example, reducing stromal density via CAF-targeted therapies could improve drug penetration into tumors.
4. Challenges: Targeting CAFs can be complex due to their heterogeneity and plastic nature. Care must be taken to avoid targeting beneficial fibroblast populations that contribute to normal tissue repair or homeostasis. Further research is needed to fully characterize the specific functions of each fibroblast subtype and to develop highly selective therapeutic agents.

17. Condition-Specific Surfaceome Markers in Colorectal Cancer CD4+ T Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers specifically enriched in CD4+ T cells isolated from normal versus tumor conditions within the colon tissue. The single-cell RNA-seq data from human colon samples, identified as being relevant to Colorectal cancer, was interrogated to find differentially expressed surface proteins in CD4+ T cells. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing a given gene (dot size) across various sub-clusters of CD4+ T cells, grouped by their original condition (normal or tumor). This approach highlights phenotypic shifts in CD4+ T cell populations in response to the tumor microenvironment.

Visual Summary

The dot plot, titled "T cell CD4+ condition-specific markers," effectively displays a clear distinction between the surfaceome profiles of CD4+ T cells in normal versus tumor conditions.

• Normal Condition Markers: A prominent cluster of genes, including SLC2A3, CCR7, CD5, CD81, PTGER4, IL6ST, CD2, and AREG, shows high mean expression (darker red dots) and a large fraction of expressing cells (larger dot sizes) in multiple CD4+ T cell sub-clusters (e.g., B_cac14, B_cac11) observed in the normal condition. These markers are largely absent or expressed at very low levels in tumor-associated CD4+ T cell sub-clusters.
• Tumor Condition Markers: Conversely, a distinct set of genes, including EMP3, FLT3LG, BSG, SELPLG, CCR6, SIRPG, RNF167, BST2, and LMAN2, exhibits high mean expression and prevalence predominantly in CD4+ T cell sub-clusters (e.g., T_cac16, T_cac9) from the tumor condition. These markers are mostly downregulated or absent in normal CD4+ T cell sub-clusters.
• Differential Expression: The visualization clearly delineates two major groups of markers, indicating a significant reprogramming of the CD4+ T cell surface proteome in the tumor microenvironment. The color intensity and dot size demonstrate both quantitative expression changes and qualitative shifts in cell population composition.

Biological Interpretation

The observed differential expression of surfaceome markers in CD4+ T cells between normal and tumor conditions suggests distinct functional states and roles within their respective microenvironments.

Markers Enriched in CD4+ T Cells from Normal Colon Tissue

These markers generally reflect the presence of naive, central memory, or homeostatically maintained T cells, capable of immune surveillance and responsiveness.

CCR7 (Chemokine Receptor 7)

• Signaling Pathways: G-protein coupled receptor signaling, mediating chemotaxis in response to CCL19 and CCL21.
• Role in TME: In normal tissue, high CCR7 expression is characteristic of naive and central memory T cells, critical for their homing to secondary lymphoid organs (e.g., lymph nodes) to encounter antigens and initiate immune responses. Its prevalence in normal colon CD4+ T cells indicates a healthy immune surveillance state.
• Therapeutic Potential: While not a direct therapeutic target for cancer, maintaining populations of CCR7+ T cells or modulating their trafficking could be beneficial for reinforcing anti-tumor immunity.
• Relevant Agents: N/A for direct targeting in cancer therapy, but used as a marker for T cell phenotypes.
• Reference: GeneCards: CCR7

CD5 (T-cell surface glycoprotein CD5)

• Signaling Pathways: T cell receptor (TCR) signaling, acts as a negative regulator of TCR signaling.
• Role in TME: A pan-T cell marker, CD5 is widely expressed on most T cells and a subset of B cells. It is involved in thymocyte development and modulating the activation threshold of peripheral T cells. Its strong expression in normal CD4+ T cells confirms their T cell identity and normal physiological function.
• Therapeutic Potential: Not typically a therapeutic target in cancer.
• Reference: GeneCards: CD5

CD2 (T-cell surface antigen CD2)

• Signaling Pathways: Co-stimulation of T cell activation, cell adhesion (binds to CD58/LFA-3).
• Role in TME: CD2 is an adhesion molecule and a co-stimulatory receptor. It strengthens antigen-specific T cell activation and adhesion to antigen-presenting cells (APCs). High expression in normal CD4+ T cells supports their ability to engage with APCs and mount robust immune responses.
• Therapeutic Potential: Less direct targeting in cancer, but its role in T cell activation is fundamental.
• Reference: GeneCards: CD2

CD81 (Tetraspanin-28)

• Signaling Pathways: Tetraspanin-mediated signaling, involved in cell adhesion, migration, proliferation, and differentiation. Forms complexes with other surface proteins.
• Role in TME: CD81 is a member of the tetraspanin family, which organize functional microdomains on the cell surface. It plays a role in T cell activation, differentiation, and interactions with antigen-presenting cells (APCs). Its presence on normal T cells suggests intact cell-cell communication and immune function.
• Therapeutic Potential: Emerging as a target in some contexts, but less so directly on T cells in cancer.
• Reference: GeneCards: CD81

PTGER4 (Prostaglandin E Receptor 4, EP4 type)

• Signaling Pathways: G-protein coupled receptor signaling, primarily via cAMP, responding to Prostaglandin E2 (PGE2).
• Role in TME: EP4 is a receptor for PGE2, a lipid mediator produced by various cells. In normal tissue, PGE2 signaling can have diverse roles, including immune regulation and maintaining homeostasis. While PGE2 can be immunosuppressive in the TME, its expression on normal CD4+ T cells suggests a baseline responsiveness that might be altered in disease, potentially contributing to immune modulation.
• Therapeutic Potential: EP4 antagonists are being investigated in cancer to counteract PGE2-mediated immunosuppression, aiming to restore anti-tumor immunity.
• Reference: GeneCards: PTGER4

IL6ST (Interleukin 6 Signal Transducer, gp130)

• Signaling Pathways: Common signaling receptor component for the IL-6 family of cytokines (e.g., IL-6, IL-11, LIF), activating JAK-STAT pathways.
• Role in TME: IL6ST (gp130) is a crucial signaling subunit for a range of cytokines that regulate immune cell differentiation, proliferation, and survival. Its expression in normal CD4+ T cells signifies their ability to respond to these cytokines, which are fundamental for orchestrating immune responses and maintaining immune cell populations.
• Therapeutic Potential: Targeting the IL-6/JAK-STAT pathway (e.g., through anti-IL-6R antibodies or JAK inhibitors) is explored in various cancers to modulate the inflammatory and immunosuppressive tumor microenvironment.
• Reference: GeneCards: IL6ST

Markers Enriched in CD4+ T Cells from Tumor Colon Tissue

These markers suggest a shift towards specific T cell subsets (e.g., regulatory or exhausted T cells), altered trafficking, or active participation in the pro-tumorigenic aspects of the tumor microenvironment in colorectal cancer.

BSG (Basigin, CD147)

• Signaling Pathways: Cell-cell adhesion, induction of matrix metalloproteinases (MMPs), lactate transport facilitation (via interaction with MCTs).
• Role in TME: CD147 is highly expressed on many tumor cells and immune cells, including T cells. On tumor-infiltrating CD4+ T cells, it can contribute to a pro-tumorigenic microenvironment by inducing MMPs, which facilitate tumor invasion and metastasis. It also influences metabolic reprogramming, contributing to an acidic tumor microenvironment that suppresses anti-tumor immune responses. Its high expression suggests T cells are actively participating in or adapting to the TME's aggressive features.
• Therapeutic Potential: CD147 is a promising therapeutic target due to its multifaceted roles in cancer progression, including invasion, angiogenesis, and immune evasion. Blocking CD147 can inhibit tumor growth and metastasis.
• Relevant Agents: Anti-CD147 antibodies (e.g., Metuximab) are under clinical investigation for various cancers.
• Reference: GeneCards: BSG

CCR6 (Chemokine Receptor 6)

• Signaling Pathways: G-protein coupled receptor signaling, mediating chemotaxis in response to CCL20.
• Role in TME: CCR6 is primarily expressed on Th17 cells and regulatory T cells (Tregs). Its high expression on tumor-associated CD4+ T cells suggests an enrichment or preferential migration of these subsets into the colorectal tumor. In CRC, Th17 cells can have context-dependent roles (pro- or anti-tumor), while Tregs are generally immunosuppressive, promoting tumor immune escape. High CCR6 expression points to active recruitment and retention of these cells in the TME.
• Therapeutic Potential: Targeting the CCR6/CCL20 axis could modulate the infiltration of pro-tumorigenic (e.g., Treg, certain Th17) T cell subsets into the tumor, potentially enhancing anti-tumor immunity.
• Reference: GeneCards: CCR6

BST2 (Bone Marrow Stromal Antigen 2, CD317, PDCA-1)

• Signaling Pathways: Involved in innate immunity, type I IFN signaling, and viral restriction.
• Role in TME: BST2 is expressed on various immune cells and cancer cells. While known for its antiviral role, in cancer, BST2 on tumor cells can facilitate immune evasion. On tumor-infiltrating T cells, its upregulation might signify an altered immune state, potentially related to chronic inflammation, T cell exhaustion, or interaction with viral elements or IFN-I pathway activity often present in the TME.
• Therapeutic Potential: BST2 targeting is being explored for its role in immune evasion by tumor cells. Its complex role on T cells might suggest new avenues for immune modulation.
• Reference: GeneCards: BST2

SELPLG (Selectin P Ligand, CD162, PSGL-1)

• Signaling Pathways: Cell adhesion, leukocyte rolling, inflammation. Mediates binding to P- and E-selectins on endothelial cells.
• Role in TME: PSGL-1 is crucial for leukocyte extravasation from blood vessels into inflamed tissues or tumors. Its upregulation on tumor-infiltrating CD4+ T cells might indicate enhanced trafficking of these cells into the tumor site, or a shift towards an inflammatory phenotype that promotes their adhesion to tumor endothelium.
• Therapeutic Potential: Modulating selectin-ligand interactions could affect the infiltration of immune cells into the TME.
• Reference: GeneCards: SELPLG

FLT3LG (FMS-like Tyrosine Kinase 3 Ligand)

• Signaling Pathways: Tyrosine kinase signaling, hematopoietic growth factor. Primarily stimulates proliferation and differentiation of hematopoietic stem cells and dendritic cells (DCs).
• Role in TME: While typically known for its role in myeloid cell development and DC maturation, its expression on tumor-infiltrating CD4+ T cells is notable. It might indicate a subset of T cells with unusual phenotypic plasticity, or could be secreted by T cells to recruit and activate other immune cells, such as DCs, thereby influencing the overall immune landscape of the TME. This could contribute to either anti-tumor or pro-tumor responses depending on the context of DC activation.
• Therapeutic Potential: FLT3LG is used as an adjuvant to expand DCs for cancer vaccines. Its expression on T cells presents a less explored, but potentially interesting, aspect for modulating TME composition.
• Reference: GeneCards: FLT3LG

EMP3 (Epithelial Membrane Protein 3)

• Signaling Pathways: Cell adhesion, cell growth, and differentiation. Belongs to the peripheral myelin protein 22 (PMP22) gene family.
• Role in TME: EMP3's exact role in T cells is less characterized compared to its known expression in glial cells and various cancers where it can act as either a tumor suppressor or oncogene. Its enrichment on tumor-infiltrating CD4+ T cells could signify specific T cell activation states, altered cell-cell communication within the TME, or an adaptive response to the stress of the tumor environment.
• Therapeutic Potential: Less established as a direct therapeutic target on T cells.
• Reference: GeneCards: EMP3

Clinical or Translational Implications

The identification of condition-specific surfaceome markers on CD4+ T cells provides valuable insights for understanding the immunobiology of colorectal cancer and offers potential avenues for therapeutic intervention.

• Biomarker Discovery: The distinct surfaceome profiles could serve as biomarkers to distinguish between T cells in healthy tissue and those in the tumor microenvironment. This could aid in patient stratification or monitoring treatment response. For example, high expression of BSG or CCR6 on circulating or tumor-infiltrating CD4+ T cells might indicate a more immunosuppressive or pro-tumorigenic TME.
• Therapeutic Targeting: Several tumor-enriched surface markers represent promising therapeutic targets for colorectal cancer immunotherapy:
  • BSG (CD147): Its widespread roles in tumor progression (invasion, angiogenesis, metabolic reprogramming) and immune evasion make it an attractive target. Monoclonal antibodies against CD147 could inhibit these pro-tumorigenic functions and potentially reprogram the TME.
  • CCR6: As a mediator of pro-tumorigenic T cell subset (Th17, Treg) infiltration, targeting the CCR6/CCL20 axis could limit the recruitment of immunosuppressive cells and enhance anti-tumor immunity.
  • BST2: While its role on T cells needs further elucidation, its known contribution to immune evasion on tumor cells suggests that targeting BST2 could overcome immune checkpoints and enhance anti-tumor responses.
• Immune Modulation Strategies: Understanding the functional implications of these markers can inform strategies to reprogram CD4+ T cell responses in the TME. For instance, interventions could aim to:
  • Reduce CCR6 expression or block CCL20 to prevent immunosuppressive T cell infiltration.
  • Modulate PTGER4 signaling to counteract PGE2-mediated immunosuppression and promote a more active anti-tumor CD4+ T cell response.

Further research would involve validating these markers using immunohistochemistry or flow cytometry on patient samples, and exploring the functional consequences of modulating these surface proteins in preclinical models of colorectal cancer.

18. Dysregulation of Cell Cycle Pathway Genes in Intestinal Epithelial Cells of Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression patterns of a predefined set of cell cycle-related genes within "Intestinal Epithelial cells," identified as the tumor-origin cell type, comparing "normal" and "tumor" conditions. Box plots are used to visualize the distribution of gene expression fractions per sample, with statistical significance indicated by p-values. The objective is to identify cell cycle genes showing statistically significant expression differences that may contribute to the inferred Colorectal cancer pathology.

Visual Summary

The visualization displays the expression levels of 24 selected cell cycle pathway genes across normal and tumor Intestinal Epithelial cell samples. A consistent and striking pattern is observed for all genes presented:

• Upregulation in Tumor: Every gene shown (e.g., YWHAZ, GSK3B, CCND1, ANAPC5, HDAC2, MYC, CDK4, CDK6, BUB3) exhibits significantly higher expression in the "tumor" condition compared to the "normal" condition.
• Statistical Significance: All displayed genes show a statistically significant difference in expression between the two conditions, with p-values consistently below 0.05, and many are considerably lower (e.g., p=0.0011 for YWHAZ, p=0.0015 for CCND1, p=0.0073 for MYC).
• Distribution Shifts: The box plots for tumor samples generally show higher median expression values, larger interquartile ranges, and often wider overall distributions extending to higher expression levels, indicating a broader upregulation across tumor samples compared to the more constrained lower expression in normal samples. The individual sample points (black dots) further confirm this shift, with most tumor samples clustering at higher expression values than normal samples.

Biological Interpretation

The consistent and significant upregulation of numerous cell cycle pathway genes in Intestinal Epithelial cells from tumor samples provides strong biological evidence for altered cellular proliferation and regulation in Colorectal cancer. This finding aligns directly with the hallmarks of cancer, which include sustained proliferative signaling and evasion of growth suppressors.

Key biological insights include:

• Enhanced Cell Proliferation: Genes like CCND1 (Cyclin D1), CDK4, and CDK6 are crucial regulators of the G1-S phase transition, driving cell cycle progression. Their increased expression suggests an acceleration of cell division in tumor cells, contributing to uncontrolled growth characteristic of cancer [1].
• Dysregulation of Mitotic Machinery: Upregulation of genes such as ANAPC5, ANAPC11, CDC16 (components of the Anaphase-Promoting Complex/Cyclosome), RAD21, SMC1A (cohesin complex components), and BUB3 (spindle assembly checkpoint component) points to an increased demand on the machinery responsible for chromosome segregation and mitosis. While some of these might be compensatory mechanisms to maintain genomic integrity, their overall heightened expression suggests a highly active and potentially perturbed mitotic process in tumor cells.
• Broad Signaling and Regulatory Alterations: The widespread upregulation of YWHAZ, YWHAQ, YWHAH, YWHAB, YWHAE, YWHAG (members of the 14-3-3 protein family) is notable. These proteins act as critical regulators of various cellular processes, including cell cycle, apoptosis, and signal transduction. Their upregulation can promote cell survival and proliferation, contributing to oncogenesis [2].
• Epigenetic Modulation and Oncogenic Signaling: Increased expression of HDAC1 and HDAC2 (Histone Deacetylases) indicates altered epigenetic regulation, which often promotes cancer cell proliferation and survival by silencing tumor suppressor genes or activating oncogenes [3]. The upregulation of MYC, a well-known proto-oncogene and master regulator of cell growth and metabolism, further confirms a strong pro-proliferative drive in these tumor cells [4]. GSK3B, involved in various signaling pathways including Wnt, could also contribute to altered proliferative signals.
• DNA Damage Response and Repair: PRKDC (DNA-PK catalytic subunit) is involved in DNA repair pathways. Its upregulation may reflect an increased burden of DNA damage often experienced by rapidly dividing cancer cells, along with an attempt to repair such damage to ensure cell survival.

Overall, the observed expression profiles in Intestinal Epithelial cells clearly indicate a profound shift towards an aggressive, hyper-proliferative state driven by a broad dysregulation of cell cycle control mechanisms in the tumor microenvironment.

Clinical or Translational Implications

The identified cell cycle genes, exhibiting significant upregulation in tumor-origin Intestinal Epithelial cells, represent potential biomarkers and therapeutic targets in Colorectal cancer:

• Biomarkers: Elevated expression of genes like CCND1, MYC, CDK4, and CDK6 could serve as diagnostic or prognostic markers for Colorectal cancer, potentially indicating more aggressive disease phenotypes.
• Therapeutic Targets: The consistent upregulation of CDKs (CDK4, CDK6) and HDACs (HDAC1, HDAC2) highlights them as attractive therapeutic targets. CDK4/6 inhibitors are already approved for other cancer types and are under investigation for colorectal cancer. Similarly, HDAC inhibitors are a recognized class of anti-cancer drugs. Targeting the 14-3-3 protein family or MYC, given their widespread upregulation, could also be explored as novel therapeutic strategies, though these can be challenging targets.
• Understanding Resistance: Further investigation into the specific mechanisms of cell cycle dysregulation could help understand resistance to existing therapies and inform the development of combination therapies.

References:

1. CCND1, CDK4, CDK6 in cancer: For a general overview of cyclins and CDKs in cancer: PubMed search: Cyclin D1 CDK4/6 colorectal cancer
2. 14-3-3 proteins in cancer: For a general overview of 14-3-3 proteins in disease: PubMed search: 14-3-3 proteins cancer
3. HDACs in cancer: For general information on HDACs and cancer: PubMed search: HDAC inhibitors cancer
4. MYC in cancer: For a general overview of MYC in cancer: GeneCards: MYC

19. Gene Ontology (GSA) Analysis of Intestinal Epithelial Cells in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results for Intestinal Epithelial cells, comparing three different groups against all other cells in the dataset:

1. Diploid Intestinal Epithelial cells vs. others: Highlights GO terms enriched in diploid Intestinal Epithelial cells.
2. Normal Intestinal Epithelial cells vs. others: Highlights GO terms enriched in Intestinal Epithelial cells from normal tissue.
3. Tumor Intestinal Epithelial cells vs. others: Highlights GO terms enriched in Intestinal Epithelial cells from tumor tissue, providing insight into colorectal cancer biology.

The analysis focuses on pathways enriched by *upregulated* differentially expressed genes (DEGs) in each respective group. Statistical significance is indicated by -log(p-val) and -log(q-val), where higher values signify stronger enrichment and statistical confidence.

Visual Summary

The provided bar plots illustrate the top enriched GO terms for Intestinal Epithelial cells across three distinct comparisons. Each bar represents a GO term, with its length corresponding to the negative logarithm of the p-value (-log(p-val)), and a separate panel indicating the -log(q-val) (FDR-adjusted p-value).

• Diploid_vs_others: This plot shows a limited number of significantly enriched terms (14 terms), primarily related to cell junctions, host-pathogen interactions, and general metabolic processes. The -log(p-val) values are relatively modest (ranging from ~1 to 2), and -log(q-val) is mostly very low or not visible, suggesting less robust FDR-adjusted significance for many terms.
• normal_vs_others: This plot displays a larger number of enriched terms (60 terms) compared to the Diploid_vs_others comparison. The -log(p-val) values are higher (up to >4), but similar to the diploid comparison, -log(q-val) remains relatively low for many terms, indicating that while many terms show nominal significance, their adjusted significance is weaker. Terms are diverse, spanning metabolic functions, specific absorption processes, and several disease-related pathways, including some cancer terms.
• tumor_vs_others: This plot reveals a dramatic increase in the number and statistical significance of enriched GO terms. Both -log(p-val) and -log(q-val) values are substantially higher, with -log(p-val) exceeding 10 and -log(q-val) prominently visible for many terms, signifying highly robust and statistically confident enrichments. The enriched terms are predominantly linked to fundamental cellular processes, metabolic reprogramming, and surprisingly, several neurodegenerative diseases.

Biological Interpretation

The Gene Ontology analysis provides clear insights into the functional shifts occurring in Intestinal Epithelial cells across different states, particularly in the context of colorectal cancer.

Diploid Intestinal Epithelial Cells

Diploid Intestinal Epithelial cells, compared to all other cells, show enrichment in terms reflecting their basic homeostatic functions:

• Cellular Structure and Adhesion: Terms like "Tight junction" and "Adherens junction" highlight the crucial role of these cells in maintaining the epithelial barrier and tissue integrity, which are fundamental characteristics of healthy epithelial tissue.
• Immune and Pathogen Response: Enrichment in "Pathogenic Escherichia coli infection," "Bacterial invasion of epithelial cells," "Salmonella infection," and "Antigen processing and presentation" underscores the continuous interaction of intestinal epithelial cells with the gut microbiome and their active role in innate immunity and antigen presentation within the intestinal mucosa.

Normal Intestinal Epithelial Cells

Normal Intestinal Epithelial cells, when compared to all other cells (including tumor cells), emphasize their specialized physiological roles:

• Physiological Absorption and Metabolism: Top terms such as "Aldosterone-regulated sodium reabsorption" and "Mineral absorption" directly reflect the primary functions of intestinal epithelial cells in maintaining electrolyte balance and nutrient uptake. "Nitrogen metabolism" and "Arginine and proline metabolism" point to active metabolic processes necessary for cell maintenance and function.
• Cellular Regulation: "FoxO signaling pathway" is involved in stress resistance, metabolism, and longevity, while "Apoptosis" reflects normal cell turnover and tissue homeostasis.

Tumor Intestinal Epithelial Cells

The most striking findings emerge from the analysis of tumor Intestinal Epithelial cells, reflecting hallmarks of cancer:

• Metabolic Reprogramming: Highly enriched terms like "Citrate cycle (TCA cycle)," "Pyruvate metabolism," "Arginine biosynthesis," and "Valine, leucine and isoleucine degradation" strongly indicate profound metabolic reprogramming. Cancer cells often alter their metabolism to support rapid proliferation, biomass production, and energy demands, a phenomenon known as the Warburg effect and altered amino acid metabolism [1]. "Oxidative phosphorylation" is also enriched, suggesting altered mitochondrial function.
• Protein Synthesis and Processing: The prominent enrichment of "Ribosome," "Protein processing in endoplasmic reticulum," "Spliceosome," "Protein export," "Ubiquitin mediated proteolysis," and "mRNA surveillance pathway" points to significantly upregulated protein synthesis, processing, and quality control mechanisms. This is consistent with the high proliferative rates and increased demand for cellular machinery in tumor cells [2].
• Cellular Stress and Survival: "Apoptosis" and "Cellular senescence" are present. While apoptosis is typically dysregulated in cancer (often inhibited), its presence here might reflect specific forms of cell death or stress responses within the tumor environment. Cellular senescence can act as a tumor-suppressive mechanism but also contributes to the pro-tumorigenic microenvironment.
• Unexpected Overlap with Neurodegenerative Diseases: A notable finding is the strong enrichment of pathways associated with neurodegenerative diseases such as "Parkinson disease," "Huntington disease," "Amyotrophic lateral sclerosis," "Alzheimer disease," and "Prion disease." While these diseases are not directly related to colorectal cancer pathology, the underlying molecular pathways often involve common cellular processes like protein misfolding, aggregation, mitochondrial dysfunction, oxidative stress, and ubiquitin-proteasome system dysregulation. It is plausible that the dysregulation of these fundamental cellular processes in rapidly proliferating and stressed tumor cells leads to an overlap with pathways historically annotated in neurodegenerative contexts [3]. This suggests shared mechanisms of cellular stress and altered proteostasis, rather than a direct neurological pathology.
• Infection and Inflammation: Terms like "Salmonella infection," "Coronavirus disease," and "Human cytomegalovirus infection" are present, suggesting that tumor cells might exhibit altered responses to pathogens or that chronic inflammation, often linked to infections, plays a role in colorectal cancer progression. The presence of "Colorectal cancer" itself as an enriched term directly validates the relevance of these findings to the inferred disease context.

Clinical or Translational Implications

The GSA results for tumor Intestinal Epithelial cells in colorectal cancer offer several potential clinical and translational insights:

• Therapeutic Targets: The identified pathways, particularly those related to metabolic reprogramming (e.g., TCA cycle, amino acid metabolism) and protein homeostasis (e.g., ribosome function, ER processing), represent potential vulnerabilities in tumor cells. Targeting these pathways could offer novel therapeutic strategies for colorectal cancer by disrupting essential processes required for tumor growth and survival [4].
• Biomarker Discovery: Upregulated genes contributing to these significantly enriched pathways in tumor Intestinal Epithelial cells could serve as novel diagnostic, prognostic, or predictive biomarkers for colorectal cancer, potentially aiding in early detection, monitoring disease progression, or predicting treatment response.
• Understanding Shared Cellular Mechanisms: The unexpected strong enrichment of neurodegenerative disease pathways warrants further investigation. Identifying the specific genes and mechanisms that overlap could reveal fundamental cellular stress responses or protein handling dysregulations that are common across diverse pathologies, potentially leading to a deeper understanding of cellular dysfunction in cancer and other diseases.

---

References:

1. Metabolic Reprogramming in Cancer: For a general overview, search PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=cancer+metabolic+reprogramming
2. Protein Synthesis and ER Stress in Cancer: For a general overview, search PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=cancer+protein+synthesis+ER+stress
3. Shared Mechanisms in Cancer and Neurodegeneration: For exploring overlaps in cellular stress, search PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=cancer+neurodegeneration+shared+mechanisms
4. Targeting Cancer Metabolism: For therapeutic implications, search PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=targeting+cancer+metabolism

20. Gene Set Enrichment Analysis (GSEA) of Cell Types in Colorectal Cancer

[Analysis Visualization Results]...

Analysis Overview

This dot plot displays the results of a Gene Set Enrichment Analysis (GSEA) conducted across various celltype_minor populations, comparing gene expression profiles under tumor conditions against normal conditions within the Colon tissue. The primary goal is to identify biological pathways that are significantly enriched (upregulated) or depleted (downregulated) in specific cell types when associated with colorectal cancer.

• X-axis: Represents individual cell type populations from the celltype_minor category. For each cell type, two comparisons are shown:
  • [Celltype]: normal_vs_others: This indicates pathway enrichment in the normal state of that cell type when compared to its state in the tumor condition. A blue dot signifies upregulation in the normal condition relative to tumor.
  • [Celltype]: tumor_vs_others: This indicates pathway enrichment in the tumor-associated state of that cell type when compared to its normal state. A red dot signifies upregulation in the tumor condition relative to normal.
• Y-axis: Lists the identified Gene Ontology (GO) terms or KEGG pathways that were found to be significantly enriched.
• Dot Color: Reflects the Normalized Enrichment Score (NES). A red color (positive NES) indicates that the pathway is significantly upregulated in the "test" condition (tumor-associated cells for tumor_vs_others comparisons, or normal cells for normal_vs_others comparisons). A blue color (negative NES) indicates that the pathway is significantly upregulated in the "reference" condition (normal cells for tumor_vs_others comparisons, or tumor cells for normal_vs_others comparisons). The RdBu_r colormap is used, where red corresponds to positive NES and blue to negative NES.
• Dot Size: Corresponds to the statistical significance of the enrichment, represented by -log10(p-value). Larger dots indicate a more highly significant enrichment (i.e., a smaller p-value).

This analysis provides a detailed, cell-type-specific perspective on the functional changes occurring within the colorectal cancer microenvironment.

Visual Summary

The GSEA dot plot provides a comprehensive overview of pathway dysregulation across the diverse cellular landscape of colorectal cancer.

• Widespread Pathway Reprogramming in Tumor Microenvironment: The plot reveals extensive pathway alterations across nearly all analyzed cell types in the tumor condition, indicated by the high density of large, intensely colored dots in the tumor_vs_others columns. This highlights a profound biological reprogramming within the tumor microenvironment.
• Hallmarks of Cancer in Intestinal Epithelial Cells: The Intestinal Epithelial cell: tumor_vs_others column, representing the identified tumor-origin cell type, shows prominent enrichment (large red dots) in pathways critical for cancer survival and proliferation. These include Glycolysis / Gluconeogenesis, Oxidative phosphorylation, Central carbon metabolism in cancer, PI3K-Akt signaling pathway, Wnt signaling pathway, and MAPK signaling pathway. Conversely, pathways associated with cell death, such as p53 signaling pathway, Necroptosis, and Ferroptosis, are significantly enriched in the Intestinal Epithelial cell: normal_vs_others column (large blue dots), indicating their downregulation or evasion in tumor epithelial cells.
• Activation of Cancer-Associated Fibroblasts (CAFs): Fibroblasts within the tumor microenvironment (Fibroblast: tumor_vs_others) exhibit strong enrichment in pathways consistent with their role as CAFs. Notable pathways include Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, PI3K-Akt signaling pathway, TGF-beta signaling pathway, MAPK signaling pathway, Wnt signaling pathway, and Proteoglycans in cancer. These suggest active involvement in inflammation, extracellular matrix remodeling, and pro-tumorigenic signaling.
• Immune Cell Reprogramming and Activation: Immune cell populations (T cells CD4+, T cells CD8+, B cells, Plasma cells, ILC) show distinct pathway shifts in the tumor context.
  • T cells (both CD4+ and CD8+) in the tumor exhibit enrichment in general immune activation pathways such as Cytokine-cytokine receptor interaction, Chemokine signaling pathway, T cell receptor signaling pathway, NF-kappa B signaling pathway, and PI3K-Akt signaling pathway. Notably, Th17 cell differentiation is significantly enriched in T cell CD4+: tumor_vs_others.
  • B cells and Plasma cells in the tumor microenvironment demonstrate enrichment in the B cell receptor signaling pathway and the Intestinal immune network for IgA production, suggesting an active, localized humoral immune response.
  • Several immune cell types also show enrichment in pathways related to various viral infections (e.g., Human papillomavirus infection, Herpes simplex virus 1 infection). This may reflect a generalized inflammatory response or activation of host defense mechanisms rather than direct viral infection.
• Diploid Epithelial Cell Signatures: The Intestinal Epithelial cell: Diploid: tumor_vs_others column shows some, though generally less intense, enrichment in metabolic and growth pathways compared to the overall Intestinal Epithelial cell: tumor_vs_others category, which likely includes aneuploid tumor cells. This suggests heterogeneous responses even within diploid epithelial cells in the tumor context.

Biological Interpretation

The GSEA findings offer crucial biological insights into the multifaceted nature of colorectal cancer (CRC) progression and the dynamic interactions within its microenvironment.

1. Metabolic Rewiring and Proliferation in Tumor Epithelium: The pronounced enrichment of glycolysis, oxidative phosphorylation, and central carbon metabolism in tumor Intestinal Epithelial cells highlights the Warburg effect and other metabolic adaptations that fuel the rapid proliferation and survival of cancer cells [1]. Concurrently, the activation of oncogenic pathways such as PI3K-Akt, Wnt, and MAPK signaling further solidifies a highly proliferative and aggressive phenotype. The downregulation of p53 signaling, Necroptosis, and Ferroptosis pathways in these cells indicates a successful evasion of various programmed cell death mechanisms, which is a hallmark of cancer progression.
2. Pro-Tumorigenic Stromal Activation: Fibroblasts within the CRC tumor microenvironment differentiate into Cancer-Associated Fibroblasts (CAFs), which are pivotal in promoting tumor growth and metastasis [2]. The robust activation of pathways like cytokine-cytokine receptor interaction, NF-kappa B, PI3K-Akt, TGF-beta, and Wnt signaling in these fibroblasts indicates their active role in orchestrating chronic inflammation, extensive extracellular matrix remodeling, angiogenesis, and immune suppression within the tumor niche. The enrichment of "Proteoglycans in cancer" underscores their contribution to building a supportive and pro-metastatic stromal scaffold.
3. Complex and Dysregulated Immune Landscape:
   • T Cell Function and Plasticity: The GSEA results suggest an active yet potentially dysregulated T cell response in the tumor. The enrichment of T cell receptor signaling and cytokine-cytokine receptor interaction points to ongoing T cell engagement. The specific enrichment of Th17 cell differentiation in CD4+ T cells is significant; while Th17 cells can have dual roles, in CRC, they are often linked to chronic inflammation and tumor progression rather than effective anti-tumor immunity [3].
   • Localized Humoral Immunity: The activation of the B cell receptor signaling pathway and the Intestinal immune network for IgA production in tumor-associated B cells and Plasma cells suggests a robust, likely localized, humoral immune response. The role of IgA in CRC is complex, potentially mediating both protective and pro-tumorigenic effects depending on the context.
   • Generalized Inflammatory Signatures: The recurrent enrichment of NF-kappa B signaling and pathways associated with various viral infections across multiple immune cell types may indicate a pervasive inflammatory state or activation of shared immune sensing pathways within the tumor microenvironment, rather than direct viral etiology.

Clinical or Translational Implications

These GSEA findings offer several avenues for potential clinical and translational impact in colorectal cancer management:

• Targeted Therapies: The consistent activation of key signaling pathways like PI3K-Akt, Wnt, and MAPK in both tumor epithelial cells and CAFs points to these as promising therapeutic targets. Dual targeting strategies, addressing both tumor cells and their supportive stromal components, could enhance therapeutic efficacy. Inhibitors of metabolic pathways (e.g., glycolysis) could also be explored.
• Immunotherapeutic Strategies: The distinct immune pathway signatures, particularly Th17 cell differentiation and Intestinal immune network for IgA production, highlight opportunities for refined immunotherapeutic approaches. Modulating the function of specific immune cell subsets to favor anti-tumor immunity, or targeting immune checkpoints associated with these pathways, could improve patient outcomes.
• Biomarker Identification: The identified cell-type-specific pathway enrichments, such as Proteoglycans in cancer in fibroblasts or specific metabolic pathway activation in epithelial cells, could serve as valuable prognostic or predictive biomarkers. These could aid in patient stratification, predicting treatment response, or monitoring disease progression.
• Understanding Treatment Resistance: The observed downregulation or evasion of cell death pathways (e.g., p53, Necroptosis, Ferroptosis) in tumor epithelial cells provides crucial insights into potential mechanisms of resistance to conventional chemotherapies, which often rely on inducing cell death. Developing strategies to re-sensitize tumor cells to these death pathways could represent a novel therapeutic avenue.

---

References:

[1] Hanahan, D., & Weinberg, R. A. (2019). Hallmarks of Cancer: New Dimensions. *Cell*, 178(3), 646-674. [PubMed Search: "Hallmarks of Cancer review"]

[2] Koliaraki, V., et al. (2020). Cancer-associated fibroblasts in colorectal cancer: emerging therapeutic targets. *Trends in Cancer*, 6(11), 937-951. [PubMed Search: "cancer associated fibroblasts colorectal cancer review"]

[3] Grivennikov, S. I., et al. (2010). IL-23 and IL-17 in tumor development. *Seminars in Immunopathology*, 32(4), 369-383. [PubMed Search: "Th17 cells colorectal cancer review"]

21. Discussion

The comprehensive single-cell analysis of human colon tissue provides crucial insights into the multifaceted pathogenesis of colorectal cancer (CRC). A foundational finding is the clear identification of Intestinal Epithelial cells as the tumor-origin population, exhibiting extensive aneuploidy and distinct transcriptional profiles that separate them from normal epithelial cells. This genomic instability, a hallmark of cancer, underscores the malignant transformation occurring within these cells and their central role in disease progression.

The tumor microenvironment (TME) undergoes significant remodeling. The immune landscape is largely immunosuppressive, marked by a statistically significant increase in regulatory T cells (Tregs) and pro-tumorigenic M2-like macrophage subsets (M2B, M2D), coupled with a decrease in follicular helper T (Tfh) cells. This creates an environment that dampens effective anti-tumor immunity and promotes tumor growth. Concurrently, fibroblasts are activated into cancer-associated fibroblasts (CAFs), expressing a unique set of surface markers (e.g., THY1, PDGFRB, MMP14, F3, ITGAV) that drive extracellular matrix remodeling, angiogenesis, and further contribute to immune evasion.

Cell-cell interaction analysis highlights a dramatic reprogramming of intercellular communication. Normal epithelial-immune cell interactions, including those involving immune checkpoints like HLA-E, are largely lost in the tumor context. Instead, a complex network of novel, pro-tumorigenic interactions emerges within the TME, predominantly involving aneuploid Intestinal Epithelial cells. Key interactions include PPIA-BSG, CEACAMs (CEACAM5, CEACAM6), and the CD52-SIGLEC10 immune checkpoint axis. These interactions facilitate tumor cell proliferation, invasion, and suppression of immune effector functions. The prominent involvement of PGE2 signaling via PTGER4 further emphasizes its role in fostering an inflammatory and immunosuppressive milieu. These findings often align with established CRC biology but also uncover specific ligand-receptor pairs whose dysregulation warrants deeper investigation as potential novel therapeutic targets.

Intracellular pathway analysis confirms widespread dysregulation in tumor Intestinal Epithelial cells. A significant upregulation of numerous cell cycle genes (e.g., CCND1, CDK4, CDK6, MYC, HDAC1/2) points to uncontrolled proliferation. Gene Ontology and GSEA results further reveal profound metabolic reprogramming (e.g., glycolysis, oxidative phosphorylation, central carbon metabolism) and enhanced protein synthesis/processing, all geared towards sustaining rapid tumor growth. A notable, albeit unexpected, finding from the GSA was the strong enrichment of pathways historically associated with neurodegenerative diseases (e.g., Parkinson, Alzheimer, Huntington). This overlap likely reflects shared fundamental cellular stress responses, protein misfolding, or mitochondrial dysfunction pathways that are highly active in rapidly proliferating and metabolically stressed tumor cells, rather than a direct neurological pathology of the colon, and represents an intriguing area for future comparative pathology research. Overall, the integrated analysis paints a picture of CRC as a highly complex ecosystem driven by genomic instability, altered cellular composition, and a dynamic, pro-tumorigenic communication network.

Hypotheses:

1. Aneuploid Intestinal Epithelial cells actively suppress anti-tumor immune responses through novel immune checkpoint interactions (e.g., CD52-SIGLEC10) and altered cytokine/chemokine signaling, leading to an immunosuppressive tumor microenvironment.
2. The observed expansion of regulatory T cells (Tregs) and pro-tumorigenic M2-like macrophages (M2B, M2D) in colorectal cancer is driven by specific interactions with tumor cells and cancer-associated fibroblasts (CAFs), which in turn promotes tumor growth and immune evasion.
3. Cancer-associated fibroblasts (CAFs) expressing markers like PDGFRB, MMP14, and F3 orchestrate extracellular matrix remodeling and secrete pro-tumorigenic factors, creating a supportive niche that enhances tumor cell invasion and resistance to therapy.
4. The widespread upregulation of cell cycle genes (e.g., CDK4/6, MYC, HDACs) and metabolic reprogramming pathways (e.g., glycolysis, oxidative phosphorylation) in tumor Intestinal Epithelial cells are critical for sustaining their uncontrolled proliferation and survival in colorectal cancer.
5. The prominent cell-cell interactions involving Basigin (CD147) and CEACAMs (CEACAM5/6) between tumor epithelial cells and other TME components directly contribute to tumor invasion, metastasis, and immune suppression in colorectal cancer.

Potential therapeutic targets:

1. ERBB2 (HER2): The 17q12:17q21.31 region, harboring the ERBB2 (HER2) gene, shows consistent and frequent amplification in the tumor-origin Intestinal Epithelial cells. ERBB2 is a well-established oncogene driving proliferation and survival in various cancers. Evidence: CNV heatmap and summary for Intestinal Epithelial cells (Section 4) show 17q12:17q21.31 amplification with 0.75 frequency across tumor samples. This is a known oncogenic driver in CRC. Validation: HER2-targeted therapies (e.g., trastuzumab, pertuzumab) are approved for other cancers and are in clinical trials for ERBB2-amplified CRC. Clinical trials evaluating patient response to these agents based on ERBB2 amplification status would provide direct validation.
2. CEACAM5: CEACAM5 is a classic tumor-associated antigen widely overexpressed on aneuploid Intestinal Epithelial cells. It mediates cell adhesion, promotes proliferation, survival, and contributes to immune evasion, showing strong interactions in the tumor microenvironment. Evidence: Highly expressed on tumor-associated Intestinal Epithelial cells (Section 15). Key ligand in strong tumor-specific cell-cell interactions like CEACAM5_CEACAM6 and CEACAM5_CEACAM1 (Sections 13, 14), mediating tumor cell cohesion and immune modulation. Validation: Antibody-drug conjugates (ADCs) or monoclonal antibodies targeting CEACAM5 are in clinical investigation for CRC. Testing their efficacy in preclinical models and clinical trials in CEACAM5-high CRC patients would validate its therapeutic potential.
3. CD147 (Basigin / BSG): CD147 is highly prominent in tumor-specific cell-cell interactions between aneuploid Intestinal Epithelial cells and various immune/stromal cells, including Macrophages and T cells. It induces matrix metalloproteinases (MMPs), promotes angiogenesis, inflammation, and influences tumor metabolism, contributing to invasion and immune suppression. Evidence: Strong and frequent PPIA-BSG interactions detected in tumor samples (Section 13). Upregulated on tumor-associated Intestinal Epithelial cells (Section 15) and CD4+ T cells in tumor (Section 17). Validation: Anti-CD147 antibodies have shown preclinical anti-tumor activity. Functional studies to block CD147 in CRC models, assessing its impact on invasion, MMP production, metabolic reprogramming, and immune evasion, would be crucial.
4. SIGLEC10 (CD52-SIGLEC10 axis): The CD52-SIGLEC10 interaction forms a novel inhibitory immune checkpoint prominently active between aneuploid Intestinal Epithelial cells (CD52) and T cells (SIGLEC10) in the tumor, suppressing T cell activation and promoting immune evasion. Evidence: Identified as a specific, strong cell-cell interaction in the tumor condition involving aneuploid Intestinal Epithelial cells and T cells (Section 14). Validation: Developing and testing blocking antibodies against SIGLEC10 in preclinical CRC models to reactivate anti-tumor T cell responses, potentially in combination with other immune checkpoint inhibitors.
5. PTGER4 (PGE2 Receptor 4): Prostaglandin E2 (PGE2) signaling, often via its EP4 receptor (PTGER4), is highly active in the tumor microenvironment, promoting proliferation, angiogenesis, and potent immunosuppression by driving M2 macrophage polarization and inhibiting T cell function. PGE2-PTGER4 interactions are seen with tumor epithelial cells and macrophages. Evidence: PGE2_byPTGES3_PTGER4 interactions are significant in tumor conditions, involving tumor epithelial cells and macrophages (Sections 13, 14). PTGER4 is also expressed on CD4+ T cells in normal tissue, suggesting altered regulation in tumor (Section 17). Validation: EP4 receptor antagonists, alone or in combination with chemotherapy or immunotherapy, can be tested in preclinical and clinical settings to reduce tumor-promoting inflammation and immunosuppression.
6. PDGFRB: PDGFRB is a receptor tyrosine kinase highly expressed on activated cancer-associated fibroblasts (CAFs). Its signaling drives CAF proliferation, differentiation, and survival, promoting desmoplasia, angiogenesis, and immune suppression in the TME. Evidence: PDGFRB is a highly expressed and prevalent surface marker on tumor-associated fibroblast clusters (Section 16), indicating robust activation of pro-tumorigenic CAFs. Validation: Tyrosine kinase inhibitors (TKIs) targeting PDGFR (e.g., imatinib, sunitinib) could be repurposed or specifically developed to modulate CAF activity in CRC. Testing these agents in CRC models or trials with high CAF infiltration.
7. CDK4/6: CDK4 and CDK6 are crucial regulators of the G1-S phase transition, and their expression is significantly upregulated in tumor Intestinal Epithelial cells, driving uncontrolled cell proliferation characteristic of cancer. Evidence: Box plots of cell cycle pathway genes show statistically significant upregulation of CCND1 (Cyclin D1), CDK4, and CDK6 in Intestinal Epithelial cells from tumor samples (Section 18). Validation: CDK4/6 inhibitors (e.g., palbociclib, ribociclib) are approved for other cancers and are under investigation for CRC. Testing their efficacy in CRC models and clinical trials, particularly in tumors with high CDK4/6 expression, would validate their utility.
8. M2-like Macrophages (M2B, M2D subsets): Specific M2-like macrophage subsets, M2B and M2D, are significantly increased in tumor samples. These subsets are associated with pro-tumorigenic functions, including promoting angiogenesis, immunosuppression, and extracellular matrix remodeling, thereby facilitating tumor growth and metastasis. Evidence: Box plots show statistically significant higher proportions of Macrophage (M2B) and Macrophage (M2D) in tumor samples compared to normal (Section 10). Validation: Strategies aimed at re-polarizing M2 macrophages to an M1-like anti-tumorigenic state, or depleting M2 populations (e.g., via CSF1R inhibitors), could be evaluated in preclinical CRC models and clinical trials.

Follow-up validation ideas:

1. Perform immunohistochemistry (IHC) or multiplex immunofluorescence (mIF) on human colorectal cancer tissue sections to validate the spatial co-localization and expression levels of key surface markers (e.g., CEACAM5, CD147, SIGLEC10, PDGFRB) on tumor cells, immune cells, and fibroblasts.
2. Utilize flow cytometry or mass cytometry (CyTOF) on dissociated tumor and normal colon samples to precisely quantify the proportions of T cell subsets (e.g., Tregs, Tfh, Th17) and macrophage subsets (M1, M2A, M2B, M2D) and correlate them with clinical outcomes in larger patient cohorts.
3. Conduct in vitro co-culture experiments using patient-derived organoids or cell lines of Intestinal Epithelial cells with immune cells (T cells, macrophages) and fibroblasts to functionally validate predicted cell-cell interactions (e.g., CD52-SIGLEC10, PPIA-BSG, CEACAMs) via ligand-receptor blocking antibodies or genetic knockdowns, assessing downstream signaling and functional consequences (e.g., T cell activation/exhaustion, tumor cell proliferation/invasion).
4. Employ CRISPR/Cas9 or shRNA to knock down highly expressed cell cycle genes (e.g., CDK4, CDK6, MYC, HDAC1/2) or metabolic pathway components in CRC cell lines/organoids to assess their impact on proliferation, survival, and drug sensitivity.
5. Validate recurrent CNV amplifications (e.g., ERBB2 on 17q12:17q21.31) using Fluorescence In Situ Hybridization (FISH) on tumor tissue sections, correlating with protein expression via IHC and clinical response to targeted therapies in independent patient cohorts.
6. Test the therapeutic efficacy of identified targets (e.g., anti-CEACAM5 ADC, anti-CD147 antibody, SIGLEC10 blocking antibody, PDGFR inhibitor, CDK4/6 inhibitor, EP4 antagonist) in patient-derived xenograft (PDX) or syngeneic mouse models of colorectal cancer, alone and in combination with existing standard-of-care treatments.
7. Utilize spatial transcriptomics or proteogenomics techniques to confirm the spatial organization of cell types and their interacting ligand-receptor pairs within the tumor microenvironment, providing higher-resolution evidence for the identified cell-cell interactions.

Limitations:

This report is based on a single-cell RNA-seq dataset, providing a snapshot of cellular states and interactions that do not fully capture dynamic biological processes over time. The inference of colorectal cancer and identification of tumor-origin cell types are based on computational analysis and metadata, requiring further clinical and pathological confirmation. Copy number variation (CNV) estimates and cell-cell interaction (CCI) predictions are computational and necessitate experimental validation (e.g., FISH, functional assays, spatial technologies). The assignment of cell types relies on marker gene expression and clustering, which can be limited by the resolution of the data and existing annotation knowledge. While the analysis highlights promising therapeutic targets, their efficacy and specificity need rigorous functional validation in in vitro, ex vivo, and in vivo models before clinical translation. The relatively small sample size, particularly for population-level statistics in some analyses, warrants caution in generalizing findings without broader validation cohorts. Furthermore, while the study focused on surfaceome markers, intracellular targets were not extensively profiled, potentially overlooking other therapeutic opportunities.

22. Query List

1. Show and save UMAPs for condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Intestinal Epithelial cell, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by celltype_major, celltype_minor, ploidy_dec, condition, and sample in two columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a population bar plot of T cell subsets.
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save a population bar plot of macrophage subsets.
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
11. Select Intestinal Epithelial cell, show their ploidy populations as a bar plot, and save the result.
12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cell, Fibroblast, Macrophage, T cell, and other relevant cell types. Select at most 80 cell-cell interactions per group.
13. Find cell-cell interactions involving Intestinal Epithelial cell, Fibroblast, Macrophage, T cell, and other major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
14. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Intestinal Epithelial cell, Fibroblast, Macrophage, T cell, and other major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
15. Show marker expressions for Intestinal Epithelial cell in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
16. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
17. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
18. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cell, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
19. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cell as a bar plot.
20. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.